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Abstract 
 
In this study we established the feasibility of designing a multi-element high intensity focused 
ultrasound (HIFU) device for Magnetic Resonance and an ultrasound imaging-guided trans-
rectal treatment of prostate cancer. An initial geometry was specified based on a clinical trans-
rectal HIFU device with a central open space to lodge an independent ultrasound imaging probe 
for guidance.  A parametric study was performed to determine the optimal focal length (L), 
operating frequency (f), element size (a) and central opening radius (r) of a device that would be 
capable of treating cancerous tissue within the prostate, spare the surrounding organs and 
minimize the number of elements. Images from the Visible Human Project were used to 
determine the organ sizes and treatment locations for simulation. Six virtual ellipsoidal tumors 
were located throughout a simulated prostate and their lateral and axial limit locations were 
selected as test locations. Using Tesla 1060(NVIDIA) graphics processors, the Bio-Heat Transfer 
Equation was implemented to simulate the heating produced during treatment at the test 
locations. L, f a and r were varied from 45 to 75mm, 2.25 to 3.00MHz, 1.5 to 8 times λ, 
where , and 9 to 12.5mm respectively. Results indicated that a combination of 
L, f, a and r of 68mm, 2.75MHz, 2.05λ and 9mm respectively could safely ablate tumors within 
the prostate and spare the surrounding organs. The number of therapeutic elements required for 
this device was 761.  
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Section 1: Background Information 
 
Motivation 
 
 The Canadian Cancer Society predicts that prostate cancer will be the number one 
diagnosed cancer in Canadian men (25,500 new cases predicted for 2009) and will have the third 
highest cancer mortality rating in the year 2009 (4,400 deaths predicted for 2009) of all cancer 
types in men (Public Health Agency of Canada).The Canadian Cancer society predicts that 9,900 
men at an age from 60-69 years old will be diagnosed with prostate cancer in the year 2009 
(Public Health Agency of Canada). This represents the highest number of cases of all age groups 
for men. The second highest number of predicted cases in the year 2009 is for the age group of 
70-79 years old totaling 6,700 men (Public Health Agency of Canada). The third highest number 
of predicted cases in the year 2009 is for the age group of 50-59 years old totaling 5,000 men 
(Public Health Agency of Canada).  
There are many current treatment options for prostate cancer patients. A relatively new 
treatment option for patients diagnosed with early stage prostate cancer is trans-rectal High 
Intensity Focused Ultrasound (HIFU) (Crouzet S., 2010).  Two trans-rectal HIFU systems are 
currently available; the AblathermTM (EDAP-TMS, Vaux-en-Velin, France) and the Sonablate®-
500 (SB-500; Focus Surgery, Inc., IN, USA). These two systems are intended to ablate the entire 
prostate without affecting surrounding organs. The most common associated morbidity for 
treatment with both the AblathermTM and the Sonablate®-500 systems is partial or total loss of 
potency (%43.2 of patients). Other reported effects are stress incontinence (%5.7), urinary tract 
infections (%7.1), chronic or pelvic pain (%5.7) and in more rare cases rectourethral fistula 
(%2.2) (Uchida T., 2006, Poissonnier L., 2007, Rouviere O, 2007, Blana A., 2008, Netsch C., 
2010).  Most of these effects are a result of treating the entire prostate. They can be significantly 
reduced by treating only specific areas of the prostate and therefore reducing the amount of 
ablated tissue. This will not only result in less morbidity but it will shorten the recovery times. 
This can be achieved by using a device capable of dynamically focusing the energy to limit the 
treatment to the tumor masses within the prostate and not damage surrounding prostatic tissue 
and other structures.  
Current clinical trans-rectal HIFU treatment systems use ultrasound imaging for 
treatment planning and targeting (Illing R., 2006, Poissonnier L., 2007). An ultrasound imaging 
transducer is used to determine the location of the prostate and plan the treatment locations. The 
imaging transducer is either permanently fixed in the center of the treatment applicator or it is 
inserted for treatment planning and then retracted during treatment. Another type of imaging that 
has proven quite useful for real time feedback during HIFU treatment is Magnetic Resonance 
Imaging (MRI) (Chapman A., 2007). MRI allows for targeting while providing with thermal 
information during treatment. Thermometry can be achieved by the phase shift of the protons 
signal caused by the temperature changes that can be retrieved using the MRI.  
The device proposed in this study is designed to be compatible with both MRI and 
ultrasound imaging guidance. Using both of these modalities will give physicians more control 
over the HIFU treatment and result in more accurate ablation of tumors.  Besides, having both 
imaging modalities will allow for the validation of other novel imaging techniques for the 
estimation of HIFU effects based on those modalities (Curiel L., 2009). 
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In this first section an overview of the specifications for the designed device will be 
presented. The anatomy of the prostate and surrounding tissues will be explained followed by the 
explanation of prostate cancer and its diagnoses. Current treatment options will be then detailed 
with their benefits and disadvantages. Then the underlying concepts of HIFU will be introduced 
as well as the currently available HIFU treatment options for prostate cancer.  
 
The Prostate Gland 
 
The prostate is part of the urinary tract and the reproductive system as seen in Figure 1-1 
(Martini H., 2005). The prostate is located inferior of the bladder in the urinary tract. The urethra 
passes urine by the contraction of the urogenital diaphragm which is located inferior and 
posterior to the prostate gland. The urogenital diaphragm consists of two circular bands of 
skeletal muscles which are called the external and internal urethral sphincters. The external 
urinary sphincter is located inferior to the prostate gland. It is the only voluntary controlled 
sphincter of the urogenital diaphragm and it must be relaxed to allow urination. The internal 
urinary sphincter is located superior of the prostate gland and is not under voluntary control. The 
urethra connects the urinary bladder to the penis and hence extends from the neck of the urinary 
bladder to the tip of the penis. When the urethra passes through the prostate it is named the 
prostatic urethra. The prostatic urethra is completely encapsulated by prostatic tissue.  
 
Figure 1-1. Prostate Gland Anatomy 
 
The prostate gland is also part of the reproductive system as one of the accessory glands. 
The functions of the accessory glands are to activate spermatozoa, provide the nutrients the 
spermatozoa need for motility and produce buffers that counteract the acidity of the urethral and 
vaginal contents. These glands include the seminal vesicles, the prostate gland and the 
bulbourethral glands. The prostate gland is the largest of the accessory glands. It is a muscular 
organ with a normal volume of 20 ml although it can grow up to five or six times this volume 
with increasing age. The prostate gland consists of connective tissue, muscle and prostatic 
glands. The prostatic glands produce a weakly acidic secretion which includes several 
compounds including seminalplasmin which is an antibiotic which may help prevent urinary 
tract infections in men (Martini H., 2005). This secretion is caused by peristaltic contractions of 
the muscular structure of the prostate gland. The prostate gland also encircles the ejaculatory 
duct. The ejaculatory ducts connect the ductus deferens and the seminal vesicles to the urethra. 
The ductus deferens pass posterior curving inferiorly along the lateral surface of the urinary 
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bladder toward the superior and posterior margin of the prostate gland. The ductus deferens 
transport spermatozoa to the ejaculatory ducts from the epididymis by peristalsis, as well as store 
spermatozoa. The seminal vesicles contribute 60% of the volume of semen specifically 
containing prostaglandins, clotting proteins and fructose. This composition gives spermatozoa 
nutrients and energy to mature into sperm, and is also passed by peristalsis. The bulbourethral 
glands are located inferior to the prostate gland, posterior to the urethra, superior to the base of 
the penis and are covered by the fascia of the external urethral sphincter. The bulbourethral 
glands are round in shape with a diameter approaching 10mm. The ducts of the bulbourethral 
glands are parallel to the urethra as it travels through the penis. The bulbourethral glands secrete 
thick alkaline mucus which helps to neutralize urinary acids in the urethra of the man and the 
woman and provides lubrication for the tip of the penis during intercourse (Martini H., 2005).  
The prostate has an anterior, posterior and two inferolateral surfaces. The superior portion 
of the prostate is known as the base, and the inferior portion is known as the apex. There is a 
midline depression on the posterior and superior surface of the prostate. Fat tissue is found 
anterior to the prostate in the retropubic space. Inferior of the prostate is the external urinary 
sphincter. The Denonviller' fascia, which is posterior to the prostate, separates it from the 
rectum. The inferolateral surfaces of the prostate rest on the pubis bone. The prostate is partially 
enveloped by the prostatic capsule. The prostatic capsule is the outer non-glandular portion of 
the prostate. The prostatic capsule is attached to the posterior border of the pubic bone by the 
puboprostatic ligaments. These ligaments are attached to the prostatic capsule on either side of 
the apex of the prostate and the pubis. Superior of the prostate is the internal urinary sphincter, 
the urinary bladder, the urethra, the ejaculatory ducts and the seminal vesicles.  
Urine travels through the prostatic urethra and seminal fluid travels through the 
ejaculatory ducts and the urethra. The ejaculatory ducts pierce the posterior and superior portion 
of the prostate. After travelling approximately 2cm through the prostate the ejaculatory ducts 
meet with the prostatic urethra at the verumontanum.  
There are three main zones usually referred to in the prostate. The three zones are the 
peripheral, central and the transition zones (see Figure 1-2).  
 
 
Figure 1-2. Sagital view of prostatic zones 
 
The peripheral zone is the posterior and lateral zone of the prostate and represents about 70% of 
the glandular portion of the prostate. The central zone represents 25% of the prostate gland. The 
ejaculatory ducts are located in the middle of the central zone. As seen in Figure 1-11 the inferior 
portion of both the central and peripheral zones do not include the entire prostate. The reason for 
this incomplete inclusion is that the inferior and anterior portion of these zones is embedded into 
the fibromuscular stroma. The transition zone represents between 5% and 10% of the prostate. It 
surrounds the urethra and is comprised of two independent smaller lobes. The remainder of the 
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prostate is noted on Figure 1-11 in red and is the anterior section of the prostate. This section is 
named the ventral fibromuscular zone and is not considered a glandular structure. It is the largest 
single component of the prostate, representing one third of the prostate volume, and includes the 
apex of the prostate.  
Figure 1-3 shows a transverse view of the prostate gland. The nerves supply for the 
prostate comes from the spine. The nerves travel outside the prostatic capsule and Denonvilliers' 
fascia until they perforate the capsule at the point of entry. The neurovascular bundle supplies 
part of the nervous system for the prostate and the penis. It is separated from the prostate by 
1.5mm at the base and 3mm at the apex. These nerves are part of the erectile function and if 
severed or damaged could result in erectile dysfunction (Kirby S., 2000). The prostate is also 
divided into five lobes. These five lobes are the two lateral lobes, the anterior lobe, the median 
lobe and the posterior lobe (Figure 1-3). These lobes are held together by the prostatic capsule. 
The lateral lobes partially encircle the urethra, the ejaculatory glands and the anterior lobe. The 
anterior lobe is located anterior of the urethra. The median lobe is located posterior to the urethra 
and anterior to the posterior lobe. The posterior lobe is the most posterior lobe of the prostate and 
is closest to the rectal wall. The rectum and rectal wall is located posterior of the prostate.  
 
Figure 1-3. Five lobes of the prostate 
 
Common Prostate Pathologies 
 
Benign Prostatic Hyperplasia  
  
A common prostate pathology is Benign Prostatic Hyperplasia (BPH). BPH is the 
enlargement of the prostate. This benign growth does not spread to other parts of the body, but 
BPH can enlarge the prostate enough to obstruct the urethral outlet (Black M., 2009) causing 
urine retention. Treatments for this type of abnormal growth include inserting a catheter to allow 
urine flow from the bladder, hormonal modulation to lessen the growth of the prostate and if 
necessary partial removal of some of the prostatic tissue.  
 
Prostate Cancer 
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Prostate Cancer Cells 
 
 Prostate cancer is the malignant growth of cancer cells in the prostate. Prostate cancer 
cells are highly proliferative, less differentiated than normal cells, and exhibit altered cellular 
adhesion (Tu H., 1996, Kirby S., 2000). Due to their altered cellular adhesion they are able to 
metastasize to other parts of the body throughout the lymphatic system or blood stream and 
initiate formation of secondary tumors (Kirby S., 2000).  There are two main manners in which 
cells die. These two manners are necrosis and apoptosis. Necrosis is usually a premature cell 
death caused by some external factor such as infection or trauma. Apoptosis is the natural death 
of cells. Cancer is caused by a deregulation on this natural cycle of the cell life. Cancer cells do 
not undergo apoptosis and can accumulate in the tissue that they are inside and create a tumor. In 
early stages of prostate cancer it is the inability to perform apoptosis which is more critical to the 
growth of the tumor (Tu H., 1996).  
Diagnoses 
  
Physicians have three main methods to diagnose prostate cancer. They are the digital 
rectal exam (DRE), the prostate specific antigen (PSA) test and imaging. The DRE is part a 
physical exam for males and may also be used on female patients. The DRE is performed to 
check for problems with organs in the pelvis and lower abdomen. A physician applies a lubricant 
to a gloved hand and gently inserts it into the rectum of the patient. The physician may use the 
other hand to move organs around to check them as well. In regards to the prostate gland the 
physician is looking for enlarged size of the prostate or hard lumps of tissue within the prostate. 
Hard lumps in the tissue could indicate prostate cancer since prostate tumors are usually harder 
than regular prostatic tissue. Another indicator of irregular cell activity in the prostate is the 
amount PSA in the blood stream. PSA is a protein produced by the prostate and is found in small 
quantities in the blood. A blood sample is taken from the patient and the quantity of PSA in the 
blood is measured.  
There are a number of issues in choosing a normal PSA level. The problems associated to 
this choice are a standardized measuring system and that every patient may have different normal 
levels. De Angelis et al. (2007) writes that if a PSA measurement higher than 2.5ng/ml is 
recorded than a biopsy should be considered for the patient according to the National 
Comprehensive Cancer Network of the United States (DeAngelis G., 2007). A more realistic 
approach to this problem is to measure the PSA frequently and consider a biopsy if the levels 
change dramatically from one test to the next.  A prostate biopsy occurs when a physician and a 
patient are suspect to cancerous growth within the prostate. A prostate biopsy is a procedure in 
which samples of the prostate are removed for examination by a pathologist to look for evidence 
of cancer cells in the prostate. It is also known as the prostate needle biopsy because an 18-gauge 
needle is inserted either through the urethra, the rectum or the perineum to remove test tissue 
from the prostate. The prostate needle biopsy is the most effective diagnoses for prostate cancer 
(Kirby S., 2000). A prostate biopsy can be performed under the guidance of ultrasound or 
magnetic resonance imaging (D’Amico A.V., 2000). Ultrasound guidance of prostate biopsy is 
performed by inserting an ultrasound imaging device into the urethra, the abdomen, the perineum 
or the rectum.  The most widely used technique for imaging guidance of a needle biopsy in the 
prostate is to trans-rectal imaging, since it provides the most useful diagnostic information, and it 
is the most precise method for guiding the needle to its preferred site (Melchior S.W., 1996).  
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There are four levels of prostate cancer named T1, T2, T3, and T4. T1 represents a tumor 
that is too small to see on a scan or physical exam, but may be seen in a needle biopsy or be seen 
through higher prostate specific antigen (PSA) levels, both the needle biopsy and PSA will be 
explained further in this report. T2 has three levels of diagnoses. First being when the tumor is 
only in half of one of the lobes of the prostate, second level being when the tumor is in more than 
half of one of the lobes, and the final level of T2 prostate cancer is when the tumor is in two or 
more lobes of the prostate but still contained in the prostatic capsule. T3 is the level at which the 
cancer has broken through the prostatic capsule. T4 is the level at which the cancer has affected 
other organs or tissue other than the prostate. This is the level in prostate cancer in which 
metastasis occurs. At this level the cancer cells are able to travel within the lymphatic system or 
the blood stream and are able to create secondary tumors at other sites within the body.  
Pathologist’s use the Gleason grading system to evaluate the progression of a tumor 
sample collected in a biopsy (Kirby S., 2000). The Gleason grading system is based on the 
architectural patterns of the primary and secondary cancerous tissues (first and second most 
occurring patterns) in the sample taken in the biopsy (Kirby S., 2000). The patterns are given a 
grade from one to five, one representing glands that are the most differentiated and five 
representing glands that are the least differentiated.  Figure 1-4 is a picture of the gland 
architecture represented by the Gleason score. The total Gleason score is the addition of both the 
Gleason score of the primary and secondary architectural patterns. If there is only one 
architectural pattern in the sample it will determine the primary and secondary Gleason score. 
Total Gleason scores range from two to ten. A score of one is given in the Gleason grading 
system for a pattern with glands that are of medium size, single, separated, closely packed and 
are uniformly shaped. A Gleason grade of two represents glands that are still single and separate, 
but are not as uniformly shaped as those of a Gleason score of one. A Gleason score of three 
represents a sample that has infiltration into the non-neoplastic tissue from the neoplastic tissue. 
The glands are of irregular shape and size as compared to those in a Gleason score of one or two, 
but are still single. A sample with a Gleason score of four has glands that are no longer single 
and are beginning to form large irregular glands as compared to those glands in a Gleason score 
of one to three. A Gleason score of five represents a sample that has almost no glandular 
differentiation. The tumors in these samples are composed of solid cords, or single cells. 
 
 18 
 
 
Figure 1-4. Representation of cell architecture in Gleason scoring system 
 
Current Treatment Options 
  
There are many treatment options for patient diagnosed with prostate cancer. Watchful 
waiting is the first option for patients with T1 prostate combined with hormonal therapy. 
(Chodak Gerald W., 1994) The five most commonly used treatments for prostate cancer are 
brachytherapy, external beam radiation therapy, prostatectomy, chemotherapy or high intensity 
focused ultrasound (HIFU). In all of these treatment options the prostate must be imaged to 
determine its location and current clinical state. This imaging is performed using ultrasound, 
MRI or Computed Tomography (CT) imaging. 
 
Prostatectomy 
  
Prostatectomy is the full or partial removal of the prostate gland. The procedure is used 
for local prostate cancers only. If the cancer has metastasized, T4 level of prostate cancer, then 
this treatment is not worth performing as it will only solve a local problem. Radical 
prostatectomy is the most recommended surgery for prostate cancer (Prostate Cancer Canada 
Network, Surgery, 2009). There are three types of radical prostatectomy in practice today named 
radical retropubic prostatectomy, radical perineal prostatectomy and robotic radical 
prostatectomy. Radical retropubic prostatectomy is performed by making an incision from below 
the navel to above the pubic bone in the middle of the patient. The surgeon than removes the 
prostate, the seminal vesicles and the prostatic urethra. After these tissues have been removed the 
surgeon connects the remaining part of the urethra to the bladder and inserts a catheter to help 
the urethra heal properly. Radical perineal prostatectomy is performed the exact same way as 
radical retropubic prostatectomy except that the incision is made between the scrotum and the 
anus. This surgery is commonly used for patients who have had previous abdominal surgeries 
and have extensive scar tissue on their abdomen. Radical retropubic protatectomy is the preferred 
surgery as it provides a better view of the bladder (Prostate Cancer Canada Network, Surgery, 
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2009). Erectile dysfunction is a common side effect of a radical prostatectomy procedure. A 
working erection is possible within four to twelve months after surgery and often may take up to 
two years before the nerves recover from the surgery (Prostate Cancer Canada Network, Surgery, 
2009). Erectile function may not be possible if the nerves are extensively damaged which occurs 
in %57.5 to %71.2 of patients whom chose this treatment option (Siegel T., 2001).  
For these surgeries the surgeon can choose to implement nerve sparing techniques, to 
allow erectile function as discussed earlier, by cutting very close to the capsule of the prostate 
and perhaps leave some of the prostatic tissue in the patient. This procedure is not possible for all 
patients because if the tumor is too close to the nerves it will be extremely difficult to remove it 
without damaging these nerves and if some of the prostate is left it could also leave some of the 
cancer cells. The most evident side effect of this procedure is infertility. The patient can still 
have an orgasm but his ejaculation will be dry since the vas deferens, ejaculatory ducts and 
prostate are no longer connected to the urethra. Urinary incontinence is a common side effect 
after a radical prostatectomy but after 24 months %95 of patients regain urinary control (Eastham 
J.A., 1996).  
  
External Beam Radiation Therapy 
 
 External beam radiation therapy treatment begins with treatment planning. Using CT or 
MRI images the location and size of the prostate is determined. These images are then used to 
define the treatment area and once this area is defined treatment planning is conducted to 
determine the radiation dosages and locations of the dosages. A linear accelerator is used to 
administer these doses. An image of a linear accelerator is seen in Figure 1-5.  These devices are 
in a lead and concrete walled room to ensure that their radioactive doses do not leave the room.  
 
 
 
Figure 1-5. Image of a Linear Accelerator 
 
A medical linear accelerator treatment platform consists of a bed for the patient and the 
linear accelerator itself. There are a number of linear accelerators available for medical use. The 
most commonly used accelerators for prostate cancer produce high energy x-rays. These x-rays 
are produced by accelerating electrons in a waveguide and then colliding these electrons with a 
heavy metal. This collision produces the x-ray energy. The x-rays are directed at the patient and 
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are formed using either specifically shaped lead blocks, or a multi-leaf lead collimator. Both of 
these directional options are incorporated into the head of the machine. The beam of x-ray 
energy comes out of the gantry (see Figure 1-5). The gantry is able to move completely around 
the patient allowing any angle for the beam. The bed is also able to move in any direction to 
assist in proper placement of the patient. Lasers are used to help align the patient whom is given 
permanent tattoos or marked with stickers to ensure that they are properly placed on the bed. 
This treatment is usually administered Monday to Friday for five to nine weeks depending on the 
severity of the cancer (Kirby S., 2000). Having the weekend free of treatment allows the non-
cancerous cells time to recover from the treatment as they are also being exposed to the 
radiation. Side effects of this treatment include severely urgent bowel movements (%9 after 24 
months), loss of urinary control (%3 after 24 months) and erectile dysfunction (complete 
dysfunction in %39.6 of patients after 24 months) (Hamilton A.S., 2001).  
 
Brachytherapy 
 
 Brachytherapy and external beam radiation therapy both use doses of radiation to cause 
double stranded DNA breaks in cancer cells. These double stranded breaks occur both in the 
cancer cells and in non-cancerous cells. The reasons that most non-cancerous cells are not killed 
during this process of radiotherapy are that non-cancerous cells repair, reoxygenate, reassort, and 
repopulate better than cancer cells after radioactive treatment (Kirby S., 2000). To treat tumors 
using brachytherapy an extensive treatment plan needs to be completed with information taken 
from ultrasound, CT or MRI images. This plan will govern the amount of radiation to be 
administered to certain areas of the prostate and how it will be administered. The two 
brachytherapy treatment types for prostate cancer are permanent seed implant brachytherapy and 
temporary brachytherapy. Permanent seed implant brachytherapy involves implanting seeds of 
radioactive material, commonly used isotopes are Iodine-125 and Palladium-103, into the 
prostate. Once implanted the seeds decay and emit gamma rays. These gamma rays are 
responsible for creating the double stranded breaks in the DNA of the cancer cells and non-
cancerous cells. Figure 1-6 shows an X-ray image of a patient who has permanently implanted 
seeds in his prostate. The other treatment using brachytherapy is temporary brachytherapy. 
Temporary brachytherapy is performed by inserting catheters into the prostate gland as seen in 
Figure 1-7. Once inserted inside the prostate gland the catheters can be used in a series of 
radiation treatments to provide certain doses to certain areas on the prostate. 
 
 
Figure 1-6. X-Ray of permanent seed implant brachytherapy 
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Radioactive seeds are placed inside the catheter for a pre-determined amount of time and then 
removed. After the procedure the catheters can be removed and there is no permanent radioactive 
material left inside the prostate of the patient.  
 
 
 
Figure 1-7. Catheter insertion for temporary brachytherapy 
  
The side effects to this treatment are similar to those of the external beam radiation therapy 
treatment because, just as in external beam radiation therapy, the healthy tissues are being 
exposed to radiation as well. The difference between brachytherapy and external beam radiation 
therapy is that the radiation is more concentrated within the prostate thus decreasing the radiation 
dosage to surrounding tissues. Side effects from brachytherapy include impotency (%13 of 
patients after 6 months), urination changes including increased frequency (%40 of patients after 
6 months) and burning during urination (%17 of patients after six months) (Arterbery V.E., 
1997). 
 
Chemotherapy 
 
 Chemotherapy refers to treatment performed using chemically based drugs. In the 
treatment of prostate cancer, chemotherapy is used when metastasis has occurred (T4 prostate 
cancer). Chemotherapy drugs are toxic and systemic (Prostate Cancer Canada Network, 
Chemotherapy, 2009). They affect cells that are constantly and quickly proliferating. These cells 
include cancer cells, hair cells and finger nail cells. These drugs may be used in conjunction with 
the other treatments but are only used to slow cancer growth and not expected to stop it (Prostate 
Cancer Canada Network, Chemotherapy, 2009). The most common uses of these drugs are to 
elongate and better life for as long as possible. Side effects for chemotherapy treatment include 
hair loss, finger nail loss, nausea, vomiting diarrhea and mouth sores. Chemotherapy can also 
damage white blood producing cells in bone marrow (Prostate Cancer Canada Network, 
Chemotherapy, 2009) and therefore have an effect on the patient’s ability to fight infection and 
show side effects such as anemia and fatigue. 
 
New Treatment Options 
 
 There are a number of future treatment options in investigation for the treatment of 
prostate cancer including cryotherapy, photodynamic therapy, laser induce interstitial 
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thermotherapy and radiofrequency interstitial tumor ablation. In this section these future options 
will be discussed individually.   
 
Cryotherapy 
 
 Cryotherapy is a treatment in which the cancerous tissue is cooled to -40oC to induce cell 
death by freezing to the entire prostate. There are three generations of cryosurgery that have been 
implemented beginning in the 1960’s with liquid nitrogen being used to freeze tissue without 
guidance or urethral warmers. The complications of this surgery were significant and included 
incontinence and rectourethral fistula (Han, K.R., 2003). The second generation of cryotherapy 
began in the late 1980’s and early 1990’s and included transrectal ultrasound guidance and 
urethral warmers which lessened the morbidities associated with this procedure. The recent 
generation of cryotherapy uses smaller probes, 1.5mm in diameter, to deliver argon gas and 
helium gas to reheat the tissue (Chin, J.L., 1998).  The probes are inserted into the perineum 
using a technique similar to brachetherapy. Thermocouples are also inserted through the 
perineum to tract the cooling of the prostate and to ensure surrounding tissue structures, such as 
the neurovascular bundle, are not affected. A catheter is also inserted into the urethra to ensure 
that none of the needles pierced the urethra during insertion and to warm the urethra during the 
procedure. Once all of the surgical equipment is in place the patient undergoes a freeze and thaw 
cycles to destroy the tissue. This cycle can be repeated in a particular region if the physician 
deems it appropriate and for larger prostates the probes and thermocouples are moved to treat the 
larger area.  
 Han et al. (2003) treated 106 patients and had a 12 month period of PSA follow-up. All 
patients were discharged within 24 hours after of the procedure. Associated morbidities of this 
treatment included urinary retention (%3.3), impotency (%87 of previously potent patients), and 
incontinence (%8). After 12 months %75 of patients had a PSA of 0.4ng/ml. Another multicenter 
study is ongoing to determine long term effects and success of this type of treatment.   
 
Photodynamic Therapy  
 
 Photodynamic therapy (PDT) is conducted by first injecting a drug which can be locally 
controlled by a light source. When activated by the light source these drugs create reactive 
oxygen species which results in tissue necrosis. An application which is being investigated is 
using photodynamic therapy for the treatment of localized prostate cancer. Koudinova et al. 
(2003) used Pd-Bacteriopheophorbide (TOOKAD) dissolved in Cremophor EL-based vehicle as 
the drug to create the reactive oxygen species in the mouse model for photodynamic therapy with 
TOOKAD (Koudinova, N.V., 2003). The mice in this study were implanted with a prostate 
cancer tumor. The tumors were then grown in the mice until they had reached a desirable size. 
Then the mice were injected with TOOKAD and the tumor was exposed to one of two light 
sources which had a wavelength of 650-800nm and 770nm, respectively, for 30 minutes. In total 
%69 on the mice in this study did not re-grow the tumors after 90 days. 
 Huang et al. (2005) conducted a similar study in the canine model in which 19 healthy 
canines and 1 with prostate cancer were used to test TOOKAD-PDT. The dogs in this study 
underwent a laparotomy procedure (Chen, Q., 2002). One week post surgery the healthy canine 
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prostates were removed and it was determined that the peripheral zone of the prostate was 
destroyed with tissue damage extending into the prostatic capsule and surrounding muscular 
tissue. The cancerous canine prostate had a %25 reduction in volume but the bog died 1 week 
after due to the spread of the disease.  
  
Laser Induced Interstitial Thermotherapy 
 
 In Laser Induced Interstitial Thermotherapy (LIIT) a laser probe is used to deliver laser 
light to tumor locations within the prostate and the absorption of this light causes the tissues at 
the target site to be ablated. Two patients with localized prostate cancer have been successfully 
treated with a 1.6mm laser probe (Raz, O., 2010). The tumor locations for both patients were 
determined using MRI imaging and biopsies. Under MRI guidance, an MRI compatible metal 
catheter was inserted into the perineum of each patient using an insertion technique similar to 
brachetherapy. Once the catheter was in the correct position it was replaced by the laser 
applicator. The laser applicator was activated and using MRI thermometry, which will be 
discussed later in this report, the physician was able to track the heating of the prostatic tissue. 
The patients were imaged post-surgery and it was decided to repeat the procedure due to residual 
vascularization and shortly after the patients were discharged. MRI scans were conducted two 
weeks after the procedure and no evidence of complications were found. Also one month after 
the procedure no adverse effects were reported by the patients. Follow-up biopsies are planned 
for 6 months after the treatment to determine the efficacy of the treatment. 
 
Radiofrequency Interstitial Tumor Ablation 
 
 Radiofrequency Interstitial Tumor Ablation (RITA) technology uses radio frequency 
applicators to create heat within the tissue and create irreversible tissue damage through 
coagulative necrosis. Shariat et al. (2005) conducted a pilot study to determine the efficacy of 
this treatment for prostate cancer. The radio frequency applicators used in this study were 15-
gauge quadralupe-hook needle probes. The operating frequency of these applicators was 
460KHz. Eleven patients with non metastatic prostate cancer were included in this study. Before 
the procedure, physicians determined the cancerous tissue within the prostate through biopsies. 
For the RITA procedure a catheter was inserted into the urethra and cooled with liquid. 
Thermocouples were inserted into the prostatic tissue and surrounding tissue to measure 
temperature change. A transrectal ultrasound imaging probe was inserted for guidance and the 
radio frequency applicators were inserted into the prostate through the perineum using a 
technique similar to that of brachytherapy. The power of each applicator was raised in a stepwise 
manner until the temperature of the tip of the applicator reached 100OC and then was kept at this 
temperature for five minutes. 33 lesions were created in the 11 patients with four patients having 
two lesions, two having three lesions and four having four lesions. Twelve months after RITA 
%67 of the patients were negative for prostate cancer in the RITA treated locations following 
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biopsy. No severe complications were reported in this study but one patient experience bladder 
spasms for a week post RITA, another experienced burning during urination for a week post 
RITA and one patient had an episode of moderate constipation. 
 
High Intensity Focused Ultrasound 
 
Overview  
 
 High Intensity Focused Ultrasound refers to a treatment in which ultrasound waves are 
focused within the body causing a temperature elevation and thermal ablation of tissues. 
Ultrasound waves are mechanical waves with a frequency higher or equal to twenty kilohertz and 
are produced by a transducer. Transducers produce these sound waves through mechanical 
vibration (Hill C.R, 2004). These vibrations cause movement of the particles in the media in 
which the sound waves are propagating through. This particle movement creates the pressure 
waves which represent the acoustic energy of the source (transducer). The acoustic energy is 
focused by using a constructive interference pattern of acoustic waves. This interference pattern 
is created with natural geometrical focusing or with electrically dynamic focusing. This results in 
acoustic pressures much lower at locations in the near and far field and higher pressures at the 
focal region as seen in Figure 1-8.  
 
Figure 1-8. HIFU near and far fields 
 
The tissue at the focal region experiences a high increase of temperature which creates 
irreversible tissue necrosis (Lele, 1967). Through this phenomenon tissues at the focal region can 
be ablated with minimal affects to surrounding tissues.  
There are two ways to adjust the focal point of a transducer in body cavities: mechanical 
and electronic. The mechanical focusing implies the physical construction of a device shaped to 
make convergence of the ultrasound waves at a desired location. The second is electrical 
dynamic focusing (Diederich C.J., 1991, Chapelon J.Y., 1993). Electrical dynamic focusing uses 
an array of transducers to enable control of the phase of the signal to each transducer to cause the 
maximum summation of wave acoustic energy at the desired location (Von Ramm O.T., 1983). 
This is known as steering the acoustic field. In literature, and in the following study, each 
transducer in the array is referred to as an “element” while the whole array is referred to as the 
“transducer”.  Figure 1-9 demonstrates how electrical dynamic focusing can create a focal point 
from a flat array transducer. 
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first grating lobe can be eliminated and the possibility of secondary lesions being produced by 
grating lobes can be eradicated.  
 
Biological Effects 
 
 Ultrasound waves are known to have two major effects on biological tissue when 
propagating through them, which are mechanical absorption and cavitation (Curiel L., 2001, 
Chavrier F., 2000). Absorption is a component of attenuation and is the conversion of ultrasound 
energy into heat within the media the ultrasound energy is propagating through (Hill C.R, 2004). 
The percentage of sound that is effectively absorbed into tissue is expressed by the acoustic 
absorption coefficient, , and is found experimentally in many different tissues for use in 
calculation. The attenuation of ultrasound is exponentially related to the product of frequency of 
the wave and the depth into the tissues. The deeper into the tissues the more the energy will be 
attenuated, and for higher frequencies this attenuation will also be more important (Bamber J.C., 
1979). 
The heat distribution within tissue can be calculated using Pennes' Bio Heat Transfer 
Equation (BHTE) (Pennes H.H., 1948), given by  
 
 
                                                             (1-2) 
   
where:  
   
                            
                          
            
   
   
   
with:  
          
where:    
              
 ,  
 
The BHTE is a modification to the basic thermodynamic equation of energy conservation and is 
composed of three major components which are the heat conduction of the tissue                     
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, heat transfer from blood perfusion of the tissue 
 and the absorbed acoustic energy . The 
temperature increase produced by this external heat source can create irreversible tissue damage. 
The temperature required to produce irreversible tissue damage is a function of the exposure time 
(Lele P.P., 1967).  
Figure 1-11 shows the relationship between temperature and time for which irreversible tissue 
damage can occur. For low temperatures or short exposure times the tissue is capable of 
dissipating the heat by perfusion or conduction away from the application site and therefore the 
tissue remains undamaged and can return to its natural temperature and state. Tissue that is 
exposed to higher temperatures or relatively long exposure times can be irreversibly damaged 
due to heat accumulation. The grey area in Figure 1-11 represents tissue that can be damaged 
differently based on the nature of the cells that are being exposed. 
 
Figure 1-11. Tissue Damage as a Function of Time and Temperature 
 
When the transducer is excited, the temperature of the tissue being treated begins to 
increase at an exponential rate and once the transducer is de-energized the tissue begins to cool at 
an exponential rate. Figure 1-12 is the simulated temperature versus time at the focal point of a 
simulated HIFU transducer. At time t=5s the simulated transducer was de-energized and the 
temperature at the focal point begins to drop.  
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Figure 1-12. Tissue temperature versus time during HIFU exposure of 5s (In this simulation the 
transducer was centered in a coolant ellipse filled with water with major and minor diameters of 
3.9cm and 2.6cm, respectively which was inside of a distended rectum ellipse with major and 
minor diameters of 4.5cm and 3.2cm, respectively, and the remainder of the sound propagation 
was through fat tissue. The a density, thermal conductivity, perfusion rate, specific heat, acoustic 
coefficient, acoustic attenuation and speed of sound for this simulation can be seen in Table 3-1 
in section 3 of this report.)  
Sapareto and Dewey established an equation based on experimentation to quantify the 
amount of thermal energy applied to a volume of tissue (Sapareto S.A., 1984).  This equation is 
given by 
 
                                                                                           (1-3) 
where:  = amount of time at 43°C to have same amount of thermal dose 
  
 
 in equation 1-3 represents the amount of time tissues should remain at 43oC to have the same 
thermal energy applied at a given temperature, T, and exposure duration dt. This is defined as the 
thermal dose. The thermal dose is usually given in equivalent minutes (EM). A thermal dose of 
240 EM is considered as the threshold for predicting lesion formation due to HIFU exposures 
(Damianou C., 1994).    
The other major biological effect produced by HIFU is cavitation. Cavitation is the 
expansion, creation or distortion of a new surface within a liquid (Leighton T.G., 1994). In the 
case of tissues it is the distortion of micro bubbles already present within the tissue. There are 
two types of cavitation which are inertial and non-inertial. Non-inertial cavitation occurs when 
the bubbles inside of an acoustic wave absorb and scatter the acoustic wave (Leighton T.G., 
1994). This type of cavitation causes the bubbles to expand and contract at an oscillating pattern. 
Non-inertial cavitation does not cause the collapse of the bubbles but can change the volume of 
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the bubbles within the tissue. The second type of cavitation is inertial cavitation. There are two 
phases to inertial cavitation which are the initial explosive growth and the collapse of the bubble 
(Leighton T.G., 1994). The initial explosive growth occurs just before the collapse of the bubble. 
This growth occurs during the rarefaction phase of the acoustic wave. The bubble reaches a 
maximum size and the compression phase of the acoustic wave halts its explosion. The bubble 
then attains a second maximum size during the next rarefaction phase of the acoustic wave and 
then collapses in the following compression phase. The pressures and temperatures that can be 
reached by this collapse can be between 1000 and 70 000 bars and 1000oK to 20 000oK (Flynn 
H.G., 1982). This rather explosive collapse takes place in a very small volume of a fraction of 
micrometers. 
Cavitation occurs in any biological media which is in the presence of an acoustic field. Non-
inertial cavitation occurs when the intensity of the acoustic field is relatively low. When the 
acoustic intensity is relatively high inertial cavitation occurs and the micro bubbles will rupture. 
This rupture causes irreversible tissue damage as it creates elevated temperatures and pressure 
(Curiel L., 2001). 
 
Treatment of Prostate Cancer Using High Intensity Ultrasound 
 
Transurethral Probes 
  
Transurethral HIFU Probes 
  
When the HIFU transducer is inserted into the urethra to ablate prostatic tissue they are 
considered a transurethral device. In this type of device there is usually no focusing of the 
ultrasound beam and the device is a flat surface that sends ultrasound which is mostly absorbed 
at the vicinity of the device. The ultrasound frequency is usually close to 8MHz in order to 
ensure enough heating of tissue close to the transducer (due to high attenuation of high 
frequencies). Different devices and procedures intended for the treatment of prostate cancer 
using transurethral high intensity ultrasound are currently undergoing their preliminary clinical 
testing (Chopra, R., 2009, Ross, A.B, 2004). For these referred approaches, MRI is used for 
guidance and temperature feedback. 
The following types of devices and procedure were used for testing in the canine model. 
Ross et al. (2004) developed two types of transurethral probes one being a sector based array 
with 90o directivity and the other being a planar transducer array. Two sector based arrays were 
tested. Both arrays had an outer diameter of 3.5mm and length of 10mm. The two operating 
frequencies tested for these arrays were 8.6 and 8.3MHz. Two planar arrays were tested both of 
which had the same outer diameter and length as the sector based arrays. One of the planar arrays 
was tested with operating frequencies of 8.0 and 8.1MHz and the other was tested with operating 
frequency of 7.8MHz. Attached to the end of each device is a urinary retention bladder. After the 
device was inserted into the urethra the urinary retention bladder was inflated. MRI was then 
used to ensure that the active surface of the device was in the proper position. Surrounding the 
active surface of the transducer is a balloon filled with coolant liquid. A constant supply of 
degassed water flows within this balloon for cooling the device and for acoustic coupling 
between the transducer and the tissue. The device is then used to ablate tissue within the prostate 
with MRI thermometry feedback. This ablation was done by mechanically rotating the device to 
different locations of the prostate after the ablation of the current location is confirmed using 
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MRI thermometry. Both the sector based array and planar array were capable of ablating the 
canine prostatic tissue. The sector based arrays were less selective than the planar arrays, but 
required less rotation for treating treatment and therefore less treatment time. The planar arrays 
were more selective but required more treatment time to cover similar treatment regions as 
compared to the sector based array. This device is not focused which limits the treatment area 
selection.  
Another transurethral probe intended for prostate treatment has been designed by Chopra 
et al. (2009) and it has been tested in vivo in the canine model. This device has only one surface 
element. The transducer of this probe is a flat element transducer that is 3.5mm x 15mm in 
surface area and has an operating frequency of 9.1 MHz. The acoustical energy produced by this 
device does not have a focal region. This device is intended for use in a guided intervention 
using MRI thermometry. The device consists of an MRI-compatible heating applicator, a rectal 
cooling device, an MRI-compatible rotational positioning system, cooling systems for circulating 
temperature-controlled water through the rectal and urethral devices, radio frequency electronics 
and hardware for ultrasound generation and motor control and computers and software interfaced 
with the MR imager for real-time processing of images and temperature maps during treatment. 
The acoustical power was controlled with input from the MRI thermometry feedback to control 
the temperature. This study successfully demonstrated the feasibility of using active MR 
temperature feedback with transurethral ultrasound therapy for targeted therapy of the prostate 
gland in the canine model. A different version of this device may soon be in clinical use under 
the company name Profound depending on the results of the clinical trials testing currently on 
going.  
 
Trans-rectal Probes 
 
Trans-rectal HIFU probes have been in commercial use for over a decade (reviewed in 
Kennedy J. E., 2005).  The current HIFU trans-rectal treatment approaches ablate the entire 
prostate gland in order to destroy the malignant tissue. There are two commercially available 
trans-rectal HIFU systems; the AblathermTM (EDAP-TMS, Vaux-en-Velin, France) and the 
Sonablate®-500 (SB-500; Focus Surgery, Inc., IN, USA). 
 
AblathermTM System 
 
 The original AblathermTM trans-rectal system shown in Figure 1-13 included a patient 
bed, a monitor to display the ultrasound image provided by a trans-rectal probe with a retractable 
imaging transducer and a treatment transducer. As shown in Figure 1-14, the treatment and the 
imaging transducer were independent and had to be switched between treatment and imaging 
modes during the therapy (Gelet, 1999). The transducer was a single-element device with a focal 
length of 40mm, a 50mm aperture which was truncated at 31mm and operated at 3MHz. 
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Figure 1-13. AblathermTM HIFU Treatment Platform 
 
AblathermTM systems of this generation are currently being used in Europe, Asia, Canada 
and Mexico. At the beginning of the procedure, the patient is placed under spinal anesthesia to 
avoid movement during the procedure and an intravenous sedation to calm the patient as the 
treatment may last from two to three hours. A catheter is inserted into the prostatic urethra so 
that the procedure does not damage the urethra and to allow urination since the procedure causes 
swelling of the prostate. This catheter is typically removed after two weeks. The probe is coated 
with a gel wrapped with a latex condom that is filled with a cooling liquid and inserted into the 
rectum of the patient by an urologist using a robotic arm. An ultrasound imaging probe is used to 
locate the apex and the base of the prostate.  Figure 1-14A shows an image of the imaging probe 
and treatment probe and Figure 1-14B shows the imaging transducer locating the apex region of 
the prostate. 
 
 
            A          B 
Figure 1-14. (A)AblathermTM Trans-rectal Probe (B) Imaging Transducer Locating Apex of 
Prostate 
 
The physician decides which regions to treat. The physician also specifies the rectal wall 
thickness as a security distance so that the rectum is not damaged. The probe is then switched to 
the exposure transducer. The transducer generates a series of high intensity ultrasound exposures 
of five seconds at each of the locations chosen by the operator followed by 5-s wait time 
between exposures. This allows enough time for the blood to remove heat between exposures 
and reduce the heat accumulation (Pichardo S., 2007).  
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At its first version, this treatment lacked real time imaging during the procedure. 
Pichardo et al. (2008) proposed an extension to this device in which the imaging device is 
permanently fixed to the center of the treatment transducer and not retracted during the 
treatment, (see Figure 1-15). 
 
 
Figure 1-15. Real-time imaging probe. (Pichardo S., 2007) 
 
This device can provide real time ultrasound imaging during the procedure. This device is now 
currently in use and some patients that were treated with this device were included in an outcome 
study for trans-rectal HIFU surgery. (Crouzet S., 2010). A clinical study using both versions of 
the AblathermTM system showed comparable clinical outcomes. In this study, 803 patients from 
urological departments in Montpellier, Marseille, Lyon, Bordeaux, Nice and Toulouse France 
were treated with the first version (Ablatherm Maxis) or the second version (Pichardo S., 2008) 
of the Ablatherm system. The patients in this study were placed into D’Amico’s risk groups 
based on the growth and spread of their prostate cancer. The bio-chemical free survival rate 
(BCFSR) was used to determine the effectiveness of the treatment. The BCFSR is a successive 
measurement of the PSA levels of a patient post operatively. The BFCSR after 7 years of the 
low, intermediate and high D’Amico risk groups in this study were 75%, 63% and 62% 
respectively. Patients with a significant increase in PSA levels, 182 patients in total, were 
considered to have failed in treatment and underwent hormonal or radiation therapy. In total 9 
patients died from cancer related illness after 8 years. 
 
Sonablate®-500 System 
 
The other commercially available device is the Sonablate®-500. The Sonablate®-500 
system consists of a coolant unit, a console for the operator, a flat screen monitor and a trans-
rectal probe which contains two transducers (Illing R., 2006)(see Figure 1-16).  
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Figure 1-16. Sonablate®-500 System 
 
The two transducers located in the trans-rectal probe are housed back to back and can have either 
a 3 cm or 4 cm focal length (Uchida T., 2006). The treatment procedure for the Sonablate®-500 
is similar to that of the AblathermTM. The patient is first given spinal anesthesia and placed in a 
supine position with their legs open. The probe is inserted manually and placed under ultrasound 
imaging guidance facing the prostate. The probe is covered with a latex balloon and liquid is 
circulated to cool the device and provide acoustical coupling for the procedure. The prostate is 
then imaged at different planes from the base to the apex. The operator defines the treatment area 
and begins treatment at the apex of the gland and finishes at the base. Usually there are three 
defined sagittal sections for the treatment that are the anterior, mid-section and posterior sections 
seen in Figure 1-17 (Uchida T., 2006). 
 
 
Figure 1-17 (Uchida T., 2006). Sagital treatment section for Sonablate®-500 HIFU surgery 
 
A clinical outcome study was also conducted for the treatment of prostate cancer using the 
Sonablate®-500 system. (Uchida T., 2006). In this study 181 patients were treated with the 
Sonablate®-500 system. Hormonal therapy was required as a salvage therapy post HIFU for 
52% of the patients. The patients in this study were also divided into D’Amico risk groups. The 
BCFSR after three years for the low, intermediate and high risk groups was 94%, 75% and 35% 
respectively. No patients died from cancer within five years after the treatment. 
 
Morbidity 
 
As for the other treatments discussed in this report there are possible complications from 
a trans-rectal HIFU procedure. The main complication for both the AblathermTM and the 
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Sonablate®-500 are partial or total loss of potency (%43.2 of patients). Other reported effects are 
stress incontinence (%5.7), urinary tract infections (%7.1), chronic or pelvic pain (%5.7) and less 
commonly rectourethral fistula (%2.20 (Uchida T., 2006, Poissonnier L., 2007, Rouviere O, 
2007, Blana A., 2008). The most prevalent morbidity associated with trans-rectal HIFU surgery 
is the loss of potency (Rouviere O, 2007). The main reason for the loss of potency after a trans-
rectal HIFU surgery is that a large percentage of the prostate is treated and the erectile nerves 
being close to the prostate they are most probably damaged during this procedure. Rectourethral 
fistulas are a rare but very severe complication of trans-rectal HIFU surgery as it requires major 
abdominal surgery. Netsch et al. (2011) conducted a study on this complication which included 
363 consecutive patients whom underwent trans-rectal HIFU surgery using the AblathermTM 
Maxis device. Of these 363 patients 8 developed a rectourethral fistula. For both the 
AblathermTM and Sonablate®-500 systems multiple HIFU sessions are sometimes required for 
adequate treatment. Netsch et al. found that the occurrence of rectourethral fistula increases with 
the increasing number of HIFU sessions.  
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Section 2: Dual-modality Image Guided High Intensity Focused 
Ultrasound Device Design for Prostate Cancer: A Numerical Study 
 
Motivation 
 
The current treatment devices for trans-rectal HIFU ablate the entire prostate gland. This 
is mainly due to the fixed focal lengths of the devices. As previously mentioned in this report, 
there is an opportunity to reduce morbidity by limiting the treatment to a reduced area. In this 
numerical study, a new optimal HIFU device is proposed to locally treat tumor masses within the 
prostate while sparing surrounding structures and healthy prostatic tissue.  
This new device is purposed to include dual-modality imaging capabilities: Magnetic 
Resonance Imaging (MRI) and Ultrasound Imaging (UI). A dual-mode imaging modality will 
allow complementing both modalities and exploring new alternatives for guidance. MRI is the 
only modality accepted by Federal Drug Administration in the USA to guide focused ultrasound 
surgery since it is able to measure temperature changes in the tissue (Hynynen K., 2010). Also, 
MRI-based techniques are exploring a much better localization of tumor masses in the prostate 
(Thoeny H.C., 2010) when compared to other imaging modalities. With standard UI, on the other 
hand, the effects of focused ultrasound on tissue are not clearly visible and tumor detection is not 
possible.  However, new UI-based techniques are emerging where tissue elasticity properties are 
measured in real-time and these properties change under the effect of HIFU (Curiel L., 2009, 
Sapin-de Brosses E., 2010). These new UI techniques can provide, with a low-cost feedback, a 
control basis for HIFU treatment. Having a dual-modality imaging device will help to validate 
these new techniques against the established standard for guidance based on MRI.  Also, the 
possibility of a complemented guidance can be considered where each modality can contribute in 
the treatment planning stages, real-time follow-up of effects and outcome assessment. 
The technical challenge in the development of a new HIFU therapeutic device with dual-
modality imaging implies that the device has to be MRI-compatible, which is ensured at 
fabrication stage, and include in its design the presence of an UI probe. The present study is 
concentrated in exploring the possibility of including this UI probe while offering the capability 
of targeting very precise regions in the prostate gland. 
The device was first designed using simulation tools. The acoustic field produced by the 
device under idealized conditions was simulated and used to determine the optimal parameters 
required for the device. Then a model of the male pelvic region was created as the testing 
environment for the device. The treatment of simulated tumors within the prostate gland was 
conducted. The resulting acoustic field and heating pattern determined the feasibility of 
designing a device that can fulfill the needs for treatment.  
 
Virtual Device Construction 
 
Virtual construction of the device began with the choice of the shape of the therapeutic 
device. The overall shape was spherical to produce a natural focus. The device was designed to 
have the same truncated width, 31mm, diameter, 50mm, and central opening diameter, 25mm, as 
the latest AblathermTM treatment probe (Pichardo S., 2008). The device was composed of 
concentric ring elements sub divided into independent elements. This is a combination of a 
spherical array and a sectorial array (Tan, 2001).  
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The surface elements used for the Rayleigh calculations had a width of λ/4. Figure 2-3 is an 
image of some of the array elements divided into surface elements used for calculations. By 
making these surface elements small compared to the distance at which the acoustic pressure is 
calculated and to the wavelength (λ) we can consider them as point acoustic sources, which is a 
criterion for the correct calculation of the Rayleigh integral.  
  
Figure 2-2. Example of Virtual Construction of Transducer 
 
 
Figure 2-3.Close up of sub-elements 
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Figure 2-5. Organ Volume Builder GUI 
 
 
Figure 2-6. Image of masks produced by “Organ Volume Builder GUI” 
 
In Figure 2-6 the yellow colored area is the mask of the bladder, the red area is the mask of the 
muscle tissue, the brown area is the rectum with the rectal wall and muscle in purple and blue 
respectively around it and the prostate gland in purple. The tissue between the prostate and the 
rectal wall is fat and was not labeled since all unlabelled space is assumed to be fat. If the user 
was not satisfied with the masks for the organs the software allowed for the revision of each slice 
of the masks. Once the user was satisfied with all of the masks for all of the selections they could 
then select the organ for which they wanted to create a volume for from the list box on the right 
side of Figure 2-6. Then the masks for each slice of the selected organ were combined into one 
mask and the organ was plotted in three dimensions as seen in Figure 2-7. The complete mask 
was then finished by using the “smooth3” Matlab function. 
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Figure 2-7. Unsmoothed Prostate 
 
The smoothed prostate gland can be seen in Figure 2-8A. This was repeated for all of the organs 
listed previously and then only a region of interest surrounding the prostate gland was sub 
selected to produce Figure 2-8B which represents the tissue that will be considered for the 
simulation of the BHTE. 
 
 
                                      A                                                                       B     
 
Figure 2-8. (A) Smoothed Prostate Gland (B) Region of Interest for Simulation 
 
Parametric Numeric Study in Water-only Conditions 
  
The diameter and truncated width of the device in this simulation were set to 50 and 
31mm, respectively, as these dimensions are those of the currently used AbathermTM device 
(Pichardo, 2008) and these parameters correlate to the anatomy of the rectum. The device 
included a central opening for an imaging probe for real time feedback of the treatment. The 
radius of the imaging central opening was set to 12.5mm to provide adequate space for lodging 
 41 
 
the currently used imaging transducer in the AblathermTM system. Figure 2-9 is a schematic of 
the chosen fixed parameters for the initial water-only condition simulation. 
 
 
Figure 2-9. Schematic of therapeutic device 
 
The operating frequency of the treatment transducer was set to 3MHz just as the AblathermTM 
treatment transducer to allow for the required treatment depth needed in this application. 
Images from the VHSMP were used to determine the position of the center of the device 
relative to the posterior and anterior surfaces of the base, center and apex regions of the prostate. 
The transducer was centered to the rectum mask and the normal vector of the transducer was 
projected into the smoothed prostate at the apex, central and base regions. The transducer was 
then rotated at each region of the prostate for the entire width of the prostate in steps of 3o. The 
intersection of the normal vector and the smoothed prostate was calculated for both the anterior 
and posterior intersections for each angle of rotation at each section of the prostate gland. Figure 
2-10 is an image of the intersection of the normal vector of the device intersecting with the 
smoothed prostate gland. The intersection is highlighted as a red triangle on the surface of the 
prostate gland. The maximum and minimum distance for the anterior and posterior intersections 
revealed the most extreme focusing distances from the surface of the device to the healthy 
prostate in the VHSMP. The intersections were found, relative form the center of the device, to 
be at 4.6 and 3.5cm for the apex, 6.5 and 3.1cm for the center, and 5.2 and 3.3cm for the base. 
These distances were used to determine the simulated HIFU treatment locations in the prostate 
and were chosen to be 2mm within the posterior and anterior limits of the prostate to safely test 
focusing at the boundaries. The calculated distances are summarized in Table 2-1. These test 
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point locations are similar to those found by Petrusca et al. (2009) for logical extreme acoustic 
test points in the prostate.   
 
Figure 2-10. Intersection of Normal Vector of Transducer Array and Central Zone of 
Prostate Gland 
 
Table 2-1. Treatment Locations for Simulation 
 
Prostate Region Posterior Distance (cm) Anterior Distance (cm) 
Base 3.5  5.0  
Center 3.3  6.3  
Apex 3.7  4.4  
 
The initial acoustic simulation was performed with a single media condition using a 
cluster computer system consisting of 16 nodes each with two quad core Xeon 5405 processors. 
Water was chosen as the propagation media with a simulated acoustic attenuation of 2.88e-
4Np/m/MHz (Hill C.R., 2004). The purpose of using water as the propagation media is that it has 
a very low acoustic attenuation and the calculations required for a single media are much simpler 
than those for multiple media. Therefore secondary lobes will be easier to find, as the sound will 
be less attenuated.  
A parametric numerical study was performed to determine the optimal combination of 
focal length and elements size that would allow performing the desired focalization without 
appearance of secondary lobes.  
The focal length was ranged from 45 to 60mm by steps of 1mm and the element size 
from 1λ to 8λ by steps of 0.5λ, where λ is the wavelength in water. In total 225 different 
combinations of focal length and element size were tested. The acoustic field was simulated 
using equations 2-1 and 2-2 (Rayleigh-Sommerfeld diffraction integral). The degree of focusing 
was quantified by the ratio of the pressure at the secondary lobe over the pressure at the primary 
lobe (η), given by 
 
               (2-3) 
 where:  
                         
 43 
 
 
The optimal device was chosen to be the configuration with the fewest elements and value of     
 for all focusing locations. The reason for choosing the configuration with the fewest 
elements is that devices with more elements are more expensive and difficult to construct, also 
each element will require its own amplifier and connection therefore more elements will add to 
the cost and complexity of the system. A device with  will have a main lobe twice the 
acoustic intensity of the secondary lobe. In a single media condition this will enable the device to 
produce a primary lobe at the target site without producing secondary lesions.   
The parameters for the optimal device resulting from this study are summarized in Table 
2-2. The optimal combination of focal length and element size was found to be 51mm and 3.1λ, 
respectively, producing a 358-element treatment device with a maximum η of 0.48. Having 
 means that this simulated device can achieve a focalization with a primary lobe twice its 
amplitude compared to that of the secondary lobe, and can therefore safely create a lesion 
without non-desired secondary lesions in the single media condition. These parameters will be 
used as the starting point for a more realistic simulation which will include the acoustic 
attenuation of the media in a transrectal HIFU prostate cancer procedure.  
 
Table 2-2. Optimal Parameters for Water-only Condition Study 
 
Parameter Optimal Value 
 0.48 
Operating Frequency 3MHz 
Element Width 3.1λ 
Focal Length 51mm 
Truncated Width 31mm 
Diameter 50mm 
Central Opening Radius 12.5mm 
Number of Elements 358 
 
Focusing in the Pelvic Region 
  
Trans-rectal HIFU treatment in reality is not performed in a solely water media condition. 
During this procedure the rectum is filled and distended by a cooling liquid (water solution). This 
action causes the rectal wall to distend. Therefore to create a more realistic simulation of an 
acoustic field created during a trans-rectal HIFU procedure the acoustic attenuation of cooling 
liquid, rectal wall and prostate need to be considered. A second simulation was performed to 
consider these acoustic conditions.  
 The first challenge in performing this simulation was to determine the distance the sound 
wave would propagate in each media. This was done by examining images from Pichardo et al. 
(2008) and the AblathermTM (EDAP-TMS, Vaux-en-Velin, France)) website which were 
produced by the imaging probe of the AblathermTM HIFU probe. Those images are seen in 
Figures 2-11A and 2-11B. 
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                     A                                                                   B 
Figure 2-11. (A) Ultrasound image during a treatment obtained from Pichardo et. al. where A is 
the rectal wall, B is prostatic tissue and C is the urethra. (B) Images from the AblathermTM 
website (AblathermTM). The white spherical shape with a bulge in the middle is the therapeutic 
transducer and the centrally lodged imaging transducer. The red cigar shape is an image of the 
intended lesion which the transducer will produce during treatment. The distance marked by 3-
8mm is the safety distance from the rectal wall to the prostate and the distance marked by 19-
26mm is the length of the lesion inside of the prostate gland. The yellow arrows mark the 
distance from the rectal wall to the transducer surface. 
 
 Based on the images in Figure 2-11A and B, and the dimensions of the simulated transducer, it 
was determined that coolant liquid could be modeled as an elliptical cylinder with a major 
diameter of 3.9cm and a minor diameter of 2.6cm. The rectal wall thickness was then measured 
from the images acquired from the VHSMP and it was found to be approximately 0.6cm. This 
correlated to a distended rectal wall with an elliptical cylinder shape having a major diameter of 
4.5cm and a minor diameter of 3.2cm. A three dimensional representation is seen in Figure 2-12 
with the coolant ellipse (in brown), the rectal wall ellipse (in purple), the prostate (in blue) and 
the surface of the simulated transducer inside of the coolant liquid (in red).  
 
Figure 2-12. Image of the Coolant liquid (brown), distended rectum (purple), transducer (red) 
and the prostate (blue) 
 
The initial calculation was to determine if all of the transducer elements were inside of the 
coolant ellipse. If this case was true then the acoustic field was calculated using the methodology 
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explained previously using 2-1 and 2-2. The acoustic attenuation of each media was incorporated 
into (2-1) as α. The values of acoustic attenuation were used for each the media in the simulation 
are shown in Table 2-3. These values are from previous simulation work (Pichardo S., 2008). 
The rectal wall acoustic attenuation used is the same as that for muscle as the rectal wall is a 
muscular tissue.  
 
Table 2-3. Acoustic Attenuation of Media 
 
Media Acoustic Attenuation (Np/m/MHz) 
Prostate 9.0  
Rectal Wall 4.1  
Coolant Liquid (water) 2.88e-4 
 
The multiple media simulation was performed using two graphics processors (NVIDIA 
Tesla C1060) instead of the cluster used for the first simulation. For a more detailed description 
of the implementation of the GPU resource please see the acoustic field calculation algorithm 
section of the appendix. The graphics processors were used because they are less expensive and 
were capable of running the simulation approximately %60 faster than the cluster. The program 
was developed in both Matlab and Computer Unified Device Architecture (CUDA). The Matlab 
version was used for quality assessment of the CUDA version. The average percent error 
between the Matlab and CUDA programs obtained at 40 test points was %0.05 for the calculated 
acoustic pressure magnitude and %0.0027 for the phase of the acoustic field.  
As in the first simulation in water conditions the frequency was set to 3MHz, the 
diameter and truncated width of the device were set to 50 and 31mm, respectively, and there was 
a central opening in the middle of the device to lodge the imaging transducer with a radius of 
12.5mm. The parameters used for this simulation were a focal length ranging from 50mm to 
60mm by steps of 1mm and the element size from 1.5 λ to 3.5λ by steps of 0.2λ. The total 
number of simulations was 100.  
After completion of this simulation it was apparent that focusing at the farthest treatment 
area was not possible with this configuration. There was no combination of parameters that met 
the  criterion. Figure 2-13 is a three dimensional representation of the 6 dB level of the 
acoustic field in red and the surface area of the transducer. The transducer in this image has a 
focal Length of 60mm, element width of 1.5λ, a central opening radius of 12.5mm and is 
intended to focus at a treatment location that is 6.3cm away from the center of the transducer. 
This particular configuration has the furthest natural focus and the smallest element size and it 
should be the best at focusing at the furthest treatment location. However, as seen in Figure 2-13, 
there are secondary lobes located far before the desired treatment location. This would result in 
secondary lesion and is not an acceptable outcome for a treatment system.  
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Table 2-4. Optimal Parameters for Increasing Device Focus Study 
  
Parameter Optimal Value 
 0.58 
Operating Frequency  3MHz 
Element Width 2.1λ 
Focal Length 68mm 
Truncated Width 31mm 
Diameter 50mm 
Central Opening Radius 12.5mm 
Total Elements 707 
 
An acceptable degree of focusing, , could not be achieved for all treatment locations for 
any configuration. Therefore there was no configuration with these parameters that provided a 
sufficient degree of focusing. The best focusing was achieved for a device focal length of 68mm. 
 
Varying the Frequency  
  
The next simulation was performed to see if decreasing the frequency would increase the 
degree of focusing at farther treatment locations within the body. The reasoning behind this 
decision is explained by Cobbold (Cobbold R.S.C, 2007) in equations 2-4 and 2-5.  
 
         (2-4) 
          (2-5) 
 where:  = distance (cm) 
   = operating frequency (MHz) 
   = temperature dependent factor (Np/cm*MHz2)   
    
 
It can be seen from equations 2-4 and 2-5 that the distance is inversely related to the 
operating frequency of the device. Therefore decreasing the frequency should increase the 
acoustic intensity at a farther location within the body. Based on this theory the simulation was 
performed again with a frequency range from 2.25MHz to 2.75MHz in steps of 0.25MHz with a 
focal length of 68mm, a central opening radius of 12.5mm and element widths ranging from 1.5λ 
to 2.3λ by steps of 0.2λ. The optimal operating frequency based on the results of this simulation 
was found to be 2.75MHz. The parameters for the optimal device resulting from this study are 
summarized in Table 2-5. 
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Table 2-5. Optimal Parameters for Varying the Frequency Study 
 
Parameter Optimal Value 
 0.58 
Operating Frequency 2.75MHz 
Element Width 2.1λ 
Focal Length 68mm 
Truncated Width 31mm 
Diameter 50mm 
Central Opening Radius 12.5mm 
Number of Elements 590 
 
An acceptable degree of focusing, , was not achieved for all of the treatment locations 
with the same configuration. The best compromise for degree of focusing was achieved with an 
element width of 2.1λ and an operating frequency of 2.75MHz.  
 
Varying Device Diameter  
  
The purpose of this simulation was to determine if increasing or decreasing the device 
diameter provided a major benefit to the degree of focusing of the device. If the larger device 
diameter permitted a better degree of focusing then further research would be required to 
determine the compatibility of this device and the anatomy of the rectum. Increasing the 
diameter of the device allows for the addition of more transducer surface without affecting the 
central opening size for lodging the imaging transducer.  This simulation was produced using 
diameters of 40mm and 60mm diameter with a focal length of 68mm, an operating frequency of 
2.75MHz, a truncated width of 31mm and element widths ranging from 1.5λ to 2.3λ in steps 
0.2λ. The best compromise from this simulation was a device with a diameter of 60mm and an 
element width of 2.1λ. The parameters for the optimal device resulting from this study are 
summarized in Table 2-6. 
 
Table 2-6. Optimal Parameters for Varying the Device Diameter Study 
 
Parameter Optimal Value 
 0.53 
Operating Frequency 2.75MHz 
Element Width 2.1λ 
Focal Length 68mm 
Truncated Width 31mm 
Diameter 60mm 
Central Opening Radius 12.5mm 
Number of Elements 792 
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This simulation also demonstrated that the desired degree of focusing could not be reached with 
this given configuration. 
Decreasing the Central opening Radius  
  
Decreasing the central opening radius was not the desired design change to achieve an 
acceptable degree of focusing as this would lead to no longer being able to lodge the 12.5mm 
wide imaging transducer.  
We first set the frequency to 2.75MHz and the focal length to 68mm since those were the 
values closest to a successful configuration obtained from the previous results. The central 
opening radius was then ranged from 1mm to 11mm by steps of 2mm and the element width was 
ranged from 1.7λ to 2.3λ in steps of 0.2λ. The optimal parameters for a device in this simulation 
was found to be a device with a focal length of 68mm, an operating frequency of 2.75MHz , an 
element width between 2.0λ and 2.2λ  with a maximum central opening radius of 9mm.  
To more accurately determine the optimal parameters a second simulation was performed 
with the same parameters as the central opening radius simulation except the element width was 
ranged from 2.0λ to 2.2λ by steps of 0.05λ. The parameters for the optimal device resulting from 
this study are summarized in Table 2-7. 
 
Table 2-7. Optimal Parameters for Decreasing the Central Opening Radius Study 
 
Parameter Optimal Value 
 0.49 
Operating Frequency 2.75MHz 
Element Width 2.05λ 
Focal Length 68mm 
Truncated Width 31mm 
Diameter 60mm 
Central Opening Radius 9mm 
Number of Elements 761 
 
In Table 2-7 it can be seen that at an element width of 2.05λ the maximum η = 0.49. The optimal 
device parameters for the simulation were a focal length of 68mm, an operating frequency of 
2.75MHz, a diameter of 50mm, truncated width of 31mm, an element width of 2.05λ and a 
central opening radius of 9mm. This configuration will be studied in further detail to determine if 
it is capable of treating tumors within the prostate, particularly if it is capable of steering the 
focus to acceptable distances. 
 
Steering Capabilities 
 
The location of a tumors in the prostate gland will not necessarily be on a normal vector 
from the device center, therefore electrical dynamic focusing must be used to steer the location 
of the focal zone in the lateral (left to right), vertical (head to foot) and axial (anterior to 
posterior) directions. Figure 2-14 is an indication of the lateral, vertical and axial direction in 
reference to the prostate (blue), the distended rectum (purple) and the transducer (red).  
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Figure 2-14. Steering directions for prostate treatment.  Prostate in blue, distended rectum in 
purple and transducer in red. 
 
Steering the focal zone in the axial direction has already been tested in the previous simulations 
by choosing points that were between 3.3 and 6.3cm from the center of the device. To determine 
how well the focal point could be steered in the other directions the problem was divided into 
two parts. The first was to determine the amount of lateral steering capable at each of the chosen 
treatment distances. The second was to determine the maximum vertical steering capable at each 
of the axial treatment locations. The value of was again used to evaluate the degree of 
focusing. The maximum lateral and vertical steering capabilities for the chosen optimal device 
configuration (focal length of 68mm, operating frequency of 2.75MHz, diameter of 50mm, 
truncated width of 31mm, element width of 2.05λ and a central opening radius of 9mm) is 
summarized in Table 2-8. 
 
Table 2-8. Steering Capabilities of Concentric Ring Array 
 
Axial Treatment 
Distance (cm) 
Maximum Lateral Steering (mm) Maximum Vertical Steering (mm) 
3.3 12.75 16.50 
3.5 13.00 15.50 
3.7 13.00 15.50 
4.4 12.00 13.50 
5.0 11.75 3.00 
6.3 5.75 0.50 
 
Randomly Placed Array Comparison 
 
As discussed earlier in this report the spacing between elements centers in an array needs 
to be less than the wavelength of the signal being transmitted to eliminate the first grating lobe 
(see equation 1-1). Another potential solution to avoid grating lobes is to randomly place the 
transducer elements on the surface of the device. Randomly distributed arrays can produce a non 
uniform distribution of the acoustic field produced by the group of independent elements. This 
results in less constructive wave summation in the pre-focal region and hence fewer grating 
lobes.  
The possibility of the random array to produce a better degree of focusing was simulated. 
Independent circular transducer elements were placed on the excitation surface of the transducer 
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degree of focusing was achievable with the randomly distributed array produced in this 
simulation along the normal axis of the array with a maximum . 
 
Steering the Random Array  
  
To test the beam steering ability of the random array steering in both the negative and 
positive direction of each steering axis had to be examined. The reason for testing both directions 
is that due to the lack of geometrical symmetry it is possible that one direction has a better 
steering than the other. Table 2-10 is a summary of the lateral and vertical steering achieved for 
both the negative and positive direction. 
 
Table 2-10. Steering Capability of Random Circle Array 
 
Treatment Distance (cm) Maximum Lateral Steering (mm) Maximum Vertical Steering (mm) 
3.23 +16.00 +10.50 
3.5 +16.00 +8.50 
3.7 +16.00 +7.50 
4.4 +15.5 +2.00 
5.0 +10.00 +0.50 
6.3 0.00 0.00 
 
In Table 2-10 it can be seen that the randomly distributed circular element array can steer slightly 
farther away from the transducer central axis in the lateral direction than the concentric 
subdivided elements array at closer points to the transducer surface. However the randomly 
distributed circular element array cannot steer the focal region at the farthest treatment location 
(6.3cm). Also the concentric ring array was superior in steering in the vertical direction at all 
treatment distances. Therefore treatment with the randomly distributed circular element array 
would require more mechanical displacement to produce the same degree of focusing as the 
concentric subdivided elements array. Also the total active surface area is less in this 
configuration and will require a higher acoustic surface intensity for each element to produce the 
same amount of acoustic energy at the treatment site.  
 
Random Element Excitation 
 
As was seen in the Steering the Random Array simulation the random distribution 
enabled better steering of the acoustic field at test points closer to the device, but the random 
circular array of elements was unable to achieve the appropriate degree of focus for the furthest 
treatment location (6.3cm). Another idea that was explored for lowering the grating lobes due to 
concentric element design was to randomly excite elements within the concentric subdivided 
circle array. The phase of each element in the concentric subdivided elements array was 
calculated for the given test point. Then elements were randomly chosen to be excited for the 
treatment. Figure 2-16 is a three dimensional image of 512 randomly chosen elements. The red 
elements in Figure 2-16 were inactive for the simulation and the blue elements were the excited 
for therapy. The excited elements of the transducer array are colored in blue in Figure 2-16.  
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treatment. The reason for randomizing the placement of the elements was to reduce the 
constructive wave interference at locations that were not at the desired focal region. This type of 
device did not perform as well as the concentric ring array as it has less active element surface 
area and was unable to steer the acoustic field to all the desired locations.  
The randomly excited simulation was tested to try to reduce the constructive wave 
interference at locations applying the same theory that was purposed for the randomly placed 
circular array. It was hypothesized that a random selection of elements could reduce the 
undesired constructive interference whilst providing the degree of focus required for treatment. 
This simulation also did not meet the focusing requirements for a treatment device.  
The optimal focal length for focusing at all of the regions previously defined was 68mm. 
This focal length is well past the intended target range of 3.3cm to 6.3cm. Similar results were 
found by Pichardo et. al (2009) when simulating the treatment of atrial fibrillation in the heart 
using a similar device.  
In this simulation it was also observed that farther from the center of the device the 
treatment locations were, the larger the region at -6dB were in the axial direction. Figure 2-17 is 
an isosurface image at -6dB of the different acoustic fields produced at 3.3, 3.5, 3.7, 4.4, 5.0 and 
6.3cm respectively. 
 
Figure 2-17. -6dB region growth with respect to distance from the transducer 
 
This -6dBgrowth relative to treatment location distance from the transducer is occurring because 
the acoustic field is less focused at farther distances. The natural focus of this device produces an 
elliptical focal region, which becomes less focused and therefore extends in the axial region 
when treatment locations are chosen farther away from the device center.  
 Increasing the device diameter in this simulation did not improve the degree of focusing 
as well when compared to decreasing the central opening radius, even if both scenarios increased 
the surface area of the device.  
The GUI developed in this project was crucial in the creation of the multiple media 
testing environment. By downloading images from the VHSMP the user was able to select 
specific anatomical regions and organs in the body for modeling. This software gives the user 
complete freedom to develop their tissue data set and tailor it to their specific requirements. 
Future users of this software could use it to create tissue data for conducting HIFU simulations in 
different regions of the body such as the heart, liver kidneys, or to make data sets for other 
experimental simulation that do not use HIFU.  
3.27cm 
3.53cm 
3.74cm 
4.43cm 
5.01cm 
6.26cm 
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Section 3: Thermal Lesion Simulation 
 
Purpose 
 
 The expected biological effects from applying acoustic energy during a HIFU procedure 
within the male pelvis were estimated using the BHTE and the thermal dose concept (Sapareto 
S.A., 1984). However, before the thermal lesion simulation could be performed, relevant 
treatment locations were chosen for treatment of prostate cancer. Tumors were defined at 
different treatment locations within the modeled prostate from the VHSMP images.  
 
Tumor and Test Point Selection 
 
A literature review was done to determine the proper location and size of tumors for 
testing the efficiency of the designed device to produce the desired thermal effects for an 
effective treatment. Coakley et al. (2002) performed a study intended to determine prostate 
cancer tumor volumes using an endorectal coil for magnetic resonance spectroscopy imaging. In 
this study 37 patients were imaged and the location and volume of the tumors were estimated 
from the MRI images. After the imaging, the patients underwent a radical prostatectomy and a 
pathologist examined the patients removed organs. In total, fifty eight tumor nodules were found. 
Nineteen patients had a single nodule, fifteen patients had 2 nodules and three patients had 3 
nodules. Fifty one tumor nodules were found in the peripheral zone and seven were found in the 
transitional zone. The minimum, maximum and mean tumor volumes for the tumor nodules 
found in the peripheral zone of the examined prostates were 0.02cc, 3.70cc, and 0.79cc 
respectively. The minimum, maximum and mean tumor volumes for the tumor nodules found in 
the transitional zone of the examined prostates were 0.04cc, 2.70cc, and 0.80cc respectively.  
The tumor nodule sizes that were chosen for both the transitional and peripheral zone 
were the minimum, mean and maximum for each zone. For simplicity the tumor shapes were all 
considered to be ellipsoid. Figures 3-1A, B, C, D, E and F are three dimensional images of the 
tumors that were used in the thermal simulation. The tumors are shown in black and the prostate 
gland is shown in blue. Initially all of the ellipsoid tumors were chosen to have their major axis 
be in the left to right direction, but once they were modeled it was apparent that this would create 
test points in locations too similar to be of any relevance to the study. Therefore tumors 2 and 5 
were rotated and aligned as close to the prostatic capsule as possible to give a larger variance in 
the treatment locations and to test if heating close to the capsule edge was possible without 
damaging surrounding organs.  
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were defined as the axial and lateral limits of the tumors. These points were chosen because they 
will be the locations that are still part of the tumor but are closest to surrounding organs and 
healthy prostatic tissue.  Besides, treating at the lateral and axial limits will be the most 
challenging since they are the farthest points from the center of the device, therefore adequate 
focusing at these locations is the most difficult to achieve. 
 
Bio-Heat Transfer Equation 
 
As discussed earlier, the Bio-Heat Transfer Equation (BHTE) can be used for calculating 
the heating effects on biological tissue. For this study, the BHTE (3-1), was implemented using 
the numerical Finite Difference Time Difference technique defined by Yin et al. (2006) and 
calculations were performed using two graphics processors (NVIDIA Tesla C1060). For a more 
detailed description of the implementation of the GPU resource please see the BHTE calculation 
algorithm section of the appendix. Boundary conditions at the borders of the tissue volume were 
set to body temperature (37C). The discretization of the BHTE was implemented using a finite-
difference scheme. The BHTE calculation requires a number of tissue, thermo-mechanic and 
biological properties including the tissue density (ρ), thermal conductivity ( ), perfusion rate 
( ), specific heat (С), attenuation coefficient (ι), acoustic absorption coefficient (χ) and the 
speed of sound (c) in each tissue. 
 
       (3-1) 
 
Also the specific heat and density of blood is required for the BHTE calculation. Table 3-1 
shows the values for each tissue properties used in the Thermal Simulation. 
 
Table 3-1. Tissue Properties used for Thermal Simulation 
 
Property Fat Muscle Bladder Ductus 
Deferens 
Seminal 
Vescicles 
Prostate Nerve 
Bundle 
Rectal 
Wall 
Coolant 
Liquid 
Density (ρ)(kg/m3) 916 1041 1040 916 916 1045 1038 1041 1000 
Thermal Conductivity ( ) 
(W/m/K) 
0.248 0.4975 0.248 0.248 0.248 0.537 0.248 0.4975 0.5867 
Perfusion Rate ( ) 
(mL/kg/min) 
28 38 28 28 28 100 28 38 0 
Specific Heat (C)(J*kg/K) 2490 3620 2490 2490 2490 3620 2490 3620 4180 
ι (Np/m/MHz) 7.0 7.6 9.3 9.3 9.3 9 12.9 4.1 2.88e-4 
χ 0.85 0.85 0.85 0.85 0.85 0.85 0.85 0.85 1 
c (m/s) 1430 1572 1430 1430 1430 1572 1615 1572 1500 
          
Blood Specific Heat: 3840 J*Kg/K Density: 1060 Kg/m3 
Values from Table 3-1 are from Duck F.A., 1990, Pichardo S., 2009, Pichardo S., 2008 and Bamber J.C., 1979.  
  
During the trans-rectal HIFU procedure coolant liquid circulates within a balloon 
surrounding the device, therefore the properties for the coolant liquid are also required for the 
simulation and are also shown in Table 3-1. The circulation of this liquid changes the initial 
temperature of the male pelvis region pre-HIFU treatment. As it cools the device it also cools the 
rectum and surrounding tissue. The effect of this cooling was simulated in the BHTE as a 
boundary condition using a Newtonian flux convention (Pichardo, 2007).  
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Table 3-2. Tumor Information and Secondary Lesions 
 
Tumor Number Tumor Size (cc) Zonal Location Presence of Secondary Lesions 
1 0.02 Peripheral No 
2 0.79 Peripheral Yes (Failed Treatment) 
3 3.70 Peripheral Yes (Failed Treatment) 
4 0.04 Transitional No 
5 2.70 Transitional No 
6 0.80 Transitional No 
 
As shown in Table 3-2 tumors 2 and 3 failed the simulated treatment.  In the treatment of 
the posterior limits for both these tumors secondary lesions were present. This is due to the 
nature of the normal wave propagation of sound at treatment locations close to the device. The 
reason for this limited focusing close to the device is that the phase differences of the elements 
that are at the edges of the device were extremely different to those near the center. This created 
a secondary lesion at depth (approximately twice the distance to the target) behind the intended 
lesion site. Also the lateral limits for tumor 3 fail to be treated without the production of 
secondary lesions. This is due to the fact that the focal region was being steered outside of its 
safe range.  
 
Partial Excitation and Device Rotation 
 
When focusing close to the device, or at the farthest lateral limits from the device center, 
secondary lesions were observed (see Table 3-2). Two solutions were tested to correct the 
production of these secondary lesions; partial excitation of the device elements and device 
rotation.  
For the partial excitation of the device, the elements closest to the center of the device 
were excited on a percent basis to decrease the phase difference between elements. The 
maximum number of excited elements needed to be determined to minimize the acoustic 
intensity at the surface of the device. Determining this maximum number of elements was done 
by performing a number of simulations in which the number of excited elements was increased 
from %50 to %75 by steps of %1 until a secondary lesion was produced. Once a secondary 
lesion was produced the maximum number of excited elements was determined that would 
enable the formation of a lesion at the given location without producing secondary lesions. This 
simulation was performed for both posterior limits of tumors 2 and 3. Figure 3-3 shows a %56 
excitation of the device elements, 431 out of the 761 elements, which is the maximum number of 
elements that can be used for safely treating the posterior limit of tumor 3 (located at 2.2cm from 
the device center). The excited elements are colored in blue and the inactive elements are colored 
in red. The posterior limit of tumor 2 required %71 of the transducer elements (545 out of the 
761 elements) to be active in order to safely treat the location at 2.3cm from the device center.  
Treating the lateral limits of tumor 3 without producing secondary lesions was done by 
rotating the device inside the rectum. The reason for this rotation is that these locations were out 
of the range of the steering capability of the device and simulations showed that without this 
rotation, secondary lesions were being created throughout the pelvic region. These secondary 
lesions were observed in a large volume approximately 1cm anterior both above and below the 

 61 
 
The overall maximum acoustic intensity at the surface of the transducer for the creation of all the 
simulated lesions was 22.74W/cm2. This maximum occurred when focusing at the posterior limit 
of tumor 3. This intensity is high as a result of the reduced surface area on the transducer when 
only %56 of the total available surface area is being used for the creation of the lesion. 
 
Thermal Simulation Discussion 
 
 The thermal simulation was conducted to determine the heating effects of the device on 
the tissue in the male pelvis region. As outlined previously the capabilities of the device to 
produce a thermal lesions at the lateral, posterior and anterior limits of each simulated tumor 
were tested. The reason for selecting only these limits was to demonstrate the ability to focus 
throughout the tumor without having to simulate lesions over the entire simulated mass.  
The device was able to treat all but four locations at the limits of all the simulated tumors. 
The problems occurred for the locations closest to the device center in the axial direction and 
farthest from the device center in the lateral direction. The two locations closest to the device 
center in the axial direction were situated at 2.2 and 2.3cm from the center of the device. To 
solve this problem a partial excitation of the device elements was proposed. An algorithm for 
determining the optimal number of excited elements for treatment locations that are close to the 
device center needs to be developed for proper treatment of these zones. The other two locations 
that were problematic to create lesions at were the lateral limits of the largest tumor (tumor 3). 
Rotating the device allowed producing lesions at these locations without secondary effects.  
In this study the device was aligned with the center of each tumor so that the effects of 
steering the acoustic field could be tested. It was apparent in the treatment of the lateral limits of 
tumor 3 that some device rotation is required for creating lesions in targeted areas far from the 
center of the device in the lateral direction. In a practical setting it would be well advised to 
rotate the device so that the center of the device in the lateral direction is approximately aligned 
with the desired location of the lesion. This would provide a better focus and better lesion 
placement. 
The maximum, minimum and standard deviation of the lesion volumes observed was 
0.015 cc, 0.003cc and 0.003 respectively. This range in lesion volume is due to the distance of 
the desired lesion location from the center of the device in the axial direction. Lesions produced 
at a greater distance are long in the axial direction. This effect is in direct relationship to the 
elliptical focus of the device that was discussed in the acoustic simulation discussion. Another 
algorithm needs to be developed to estimate lesion size based on the target distance from the 
transducer center as it is apparent there is a large difference in their volumes.  
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Section 5:  Discussion and Conclusions 
  
The purpose of this study was to determine the feasibility of designing a new dual-
modality trans-rectal HIFU device for localized prostate cancer treatment. Development of the 
environment for this study was done suing images from the VHSMP. These images were used to 
reconstruct the organs in the male pelvis region. Also simulated tumors were placed within the 
reconstructed prostate to adequately test the treatment capabilities of the device.  
The three tested device configurations were the concentric ring array, the randomly 
placed circular elements array and the randomly excited concentric ring array. Out of the three 
tested devices the concentric ring array device was the optimal configuration for treatment of the 
prostate gland. The parameters that were varied for the parametric study of the concentric ring 
array were the focal length, the operating frequency, the element size and the central opening 
radius to lodge the imaging transducer. Determining the optimal combination of these parameters 
was done by simulating the acoustic field and calculating the ratio of the primary and the 
secondary lobes  of the acoustic field. The simulated device with the minimal amount of 
independent elements which had  was selected as the optimal device. The optimal device 
parameters that were found were a focal length of 68mm, an operating frequency of 2.75MHz, an 
elements size of 2.05λ and a central opening radius for lodging the imaging transducer of 9mm. 
The total number of independent elements for this configuration was 761. 
The random circular array was tested to observe if random elements could reduce 
secondary lobes. Due to the lack of therapeutic treatment surface area the device was not able to 
focus at the chosen test locations and the steering capability of this device was also limited due 
to the lack of symmetry of the therapeutic elements.  
The randomly excited array was also simulated to determine if random excitation could 
reduce the secondary lobes of the acoustic field. Again, just as the random circular array 
simulation, the lack of therapeutic surface area inhibited the device from focusing at all the test 
locations. Since focusing on the transducer center axis was not possible there was no need to test 
the steering capability of this randomly excited device.  
Finally a simulation of the thermal effects was conducted by implementing the Bio-Heat 
Transfer Equation to obtain the temperature rise produced by the device at different treatment 
locations. Test locations were defined in order to treat the lateral, anterior and posterior limits of 
different simulated tumors. When testing the different treatment locations the device was aligned 
to the center of the tumors. However, for the largest tumor a rotation of+ π/8 was required to 
treat both lateral limits respectively. This was required because those test locations were out of 
the steering capabilities of the device. In future applications the device should be aligned as close 
as possible to the treatment location and the electronic dynamic focusing should be used to 
further increase the focus of the device at the proper target site.  
For two of the simulated tumors the treatment of the posterior limits was not possible 
since secondary lesions appeared. These locations were at 2.2 and 2.3cm from the center of the 
device. For treating these locations the device elements were partially activated. Practically this 
device should be aligned with the desired treatment location and then the electronic dynamic 
focusing should be used to further focus the acoustic energy at the desired target. The maximum 
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steering required for a specific lesion size needs to be determined and a safety limit needs to be 
determined to optimize the treatment. Mechanical rotation should be limited but it most likely 
will be required for treating large tumor masses or prostates with multiple tumors. This 
requirement of rotation to cover this type of tumor mass is not necessary a problem. A rotation 
mechanism is still required to position the device at the center of a tumor mass. For this type of 
enlarged tumor, the treatment can be divided in sub-regions and the electronic steering will be 
able to cover the sub-regions.  
It is apparent that the simulated concentric ring array has the ability to create small 
lesions within the prostate. Further work is required to determine the optimal treatment regime 
required for treating entire tumor masses within the prostate. Parameters that need to be 
examined would include exposure time, surface intensity and maximum reached temperatures. In 
the current study the heat accumulation after successive exposures was not examined. The heat 
accumulation needs to be examined as it may have an effect on the treatment regime.  
Another consideration for the future simulation would be the locations at which partial 
percent excitation is required for adequate treatment. In the simulation presented in this paper it 
was found that treatment locations that are less than 2.3cm from the center of the device require a 
partial excitation of the independent elements on the device. However, we only tested some 
points; a more general study has to be conducted. As well, the optimal percentage of 
independently excited elements that is required for treatment at other locations has to be 
confirmed. 
After deciding upon a treatment regime based on the results of a treatment regime study, 
the next step in the development of this device would be construction and physical testing. 
Although the optimal element size is 2.05λ with a minimum element spacing of λ/4 the 
construction of the therapeutic portion of this device may not be possible due to constraints on 
the material fabrication. The constructed device may have slightly larger therapeutic elements, or 
a slightly larger spacing between elements. The impact of these variations should be studied as 
well. 
In this study we examined an optimal device that would need an ultrasound imaging 
probe smaller than the one currently used by the AblathermTM system. The existing probe is a 
linear array operating at 8MHz. The diameter of the central opening used to lodge the imaging 
probe went from 25mm to 18mm. A study can be performed to design a new imaging probe that 
can be compatible with this central opening. The size of this central opening is at least 
compatible with existing probes used in trans-esophageal imaging systems for cardiac imaging 
(Bezold L.I., 1996) which shows dimensions in the order of 13 mm, including protective case. 
On the other hand, the operating frequency of these probes is in the range between 3 and 5MHz. 
The new study can analyze the maximal frequency that can be attained with the new dimension 
of the central opening. 
Another possible solution is to fill the central opening with dual operational transducers 
that can image the prostate and treat the prostate. The elements of the device that are located near 
the center of the treatment area could be dual imaging and therapy transducer elements (Owen 
N.R., 2010).  A combination of imaging elements and imaging/therapy elements could be 
constructed in this space and used when necessary, such as for treating distant targets.  
There exists also the possibility of keeping the best device found with the central opening 
large enough the existing imaging probe. This device seems able to treat precise regions up to a 
region found at a depth of 50-mm (Figure 2-14). Deeper regions may be attained with longer 
exposures; the limitation of this approach may be that the selectivity of treating small regions 
 64 
 
will be reduced.  However, the anterior region of the prostate is surrounded by fat tissue and 
there are not delicate structures to preserve in this region. 
Another matter that has to be studied concerns the MR imaging. An MRI coil will have to 
be embedded within the device and this will certainly modify the geometrical characteristics and 
possibly impact the ergonomics of the device. The device proposed in this study is intended to 
use MRI for real time feed-back of temperature changes within the prostate and surrounding 
tissue. A complete study of the geometry and placement of the MRI coil, within the device, 
needs to be conducted to optimize the MRI imaging and to evaluate its impact on the 
performance of the device.   
The computation time for calculating the acoustic field using the GPU’s was 
approximately %60 shorter that of the cluster computer system. Having much shorter 
computation times meant that this parametric study, and any after it, could be run for larger 
variations of parameters. This gives the user of the simulation more freedom to perhaps include 
more variables in the simulation or to simulate more configurations in the same amount of time. 
Also the cost of the GPU system is considerably less than that of the cluster computer. This 
could relate to more investigators having the opportunity to simulate their ideas at an affordable 
expense and hence lessen their time in physical experimentation. The advent of using GPU’s for 
computer simulation is decreasing costs and increasing simulations times in many other 
engineering simulation applications (Walsh S.D.C., 2009) and the medical research community 
will benefit from these advances as well. 
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Appendix 
 
Numerical Implementation 
Graphics Processing Unit and CUDA 
 
NVIDIA Tesla 1060 graphics processors were used in this study for calculating the 
acoustic field and thermal effects from HIFU treatment. The reason for using these processors is 
that they are less expensive, to purchase and to house, and are suitable for high arithmetic 
applications (Owens, J., 2008). GPU’s are suitable for high arithmetic applications because, 
unlike central processing units, they pipeline tasks in space not time.  Also the amount of 
transistors dedicated to data processing in GPU’s is higher as the GPU requires less data caching 
and flow control then central processing units (CPU). The main disadvantage of a GPU is that it 
is not suitable for all computing applications, such as an operating system or network connection, 
as it is only capable of supporting mathematical and memory access instructions. There are two 
major components that execute code when using a GPU; the host, a CPU, and the device, the 
GPU. The host passes the necessary information for calculation to the device which is saved into 
memory.  
Computer Unified Device Architecture (CUDA) is a general purpose parallel computing 
architecture developed by NVIDIA to program their GPU’s in a variety of computer languages 
(Kirk, D.B, 2009). In a GPU each task is executed by a thread. All of the threads in a GPU are 
grouped together in blocks and can be indexed either one dimensionally or two dimensionally. 
The host will call functions named kernels that will be executed by the GPU using a grid block 
distribution of threads. 
The architecture of the modern GPU consists of threads, local memory, shared memory, 
global memory, constant memory, texture memory and registers (see Figure A-1). The efficient 
use of these resources is at the discretion of the programmer. The local memory is the memory 
associated to each thread inside of a block. This memory is only accessible by the thread it 
pertains to and not directly accessible to other threads within the same block. Shared memory is 
available to all of the threads within the particular block it pertains to. It is not directly accessible 
to other blocks. Global memory is available to all of the blocks within the GPU but it is a costly 
memory access and should be avoided for minimizing simulation time. Texture memory is also 
available to all of the blocks within the GPU. CUDA supports a subset of the texturing hardware 
which uses this memory which is not pertinent to this particular simulation environment. The 
registers in the GPU are another writing resource for individual threads.  
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Figure A-1. Architecture of GPU 
Threads are indexed based on a block index and a thread index (see Figure A-2). 
 
Figure A-2. Block and thread indexing for GPU. 
 The number of threads required to execute the kernel for one block of threads is the thread block 
dimension and the number of block grids required to execute the entire parallelized instruction is 
the block grid dimension. 
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Acoustic Field Calculation Algorithm 
 
 The acoustic field simulation was programmed in Matlab with a mexFunction used to 
execute the GPU code. The numerical version of (2.1) that was coded is 
 
                                (A-1)  
 
 Using a back propagation scheme the Matlab function first calculated the phase and amplitude 
of each sub-element , in the virtually constructed array, required to create a focal region at the 
desired location. Then an observation field of data points was constructed in a Cartesian three-
dimensional domain at a resolution of λ/2. This domain of data was sent to the global memory of 
the GPU.  
The mexFunction dedicated the amount of constant memory available for each block of 
the kernel computation. The data sent to the constant memory in the GPU included the phase and 
amplitude of the signal, location and surface area for each sub-element , the acoustic 
attenuation of the media in the study and the speed of sound. The constant memory allocation is 
calculated by dividing the total constant memory, 64kB, by the amount of memory required to 
allocated the data describing a sub-element . For this calculation, the maximum number of sub-
elements   that could be fitted was 2700. This implies that the kernel needs to be called enough 
times to calculate the full integral, where each time 2700 sub-elements are sent to the constant 
memory. The optimal thread block dimension was determined experimentally by running the 
simulation with different block sizes until the optimized size was determined, which was a one-
dimensional block of 256 threads. The grid dimension was calculated as follows: 
 
Block grid dimension = (number of sources – 1/thread block dimension + 1)  (A-2)  
 
Calculating the acoustic field at each observation point was done by summing the 
acoustic field from each source produced by each sub-element   in the array. As mentioned 
above, the kernel was called enough times to calculate the full contribution of the device. The 
call to the kernel was as follows: 
 
while(mr1start < mr1) 
    { 
      mr1stop = mr1start+MAX_ELEMS_IN_CONSTANT; 
      if (mr1stop >= mr1)// if the last block of data has been accessed then this is the last time the loop will run 
        { 
          mr1stop =  mr1; 
          LastPart=1; 
        } 
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ForwardPropagationKernel<<<dimBlockGrid, dimThreadBlock>>>(mr2, 
                                                                 mr1, 
                                                                 wvnbr, 
                                                                 wvnbi, 
                                                                 d_r2pr, 
                                                                 d_u2pr, 
                                                                 d_u2pi, 
                                                                 mr1step, 
                                                                 LastPart, 
                                                                 d_coolant_ellipse, 
                                                                 d_distended_ellipse, 
                                                                 prostate_attenuation); 
CHECK_LAST_ERR();// error check to ensure all calculations were done 
cudaThreadSynchronize();// this command makes sure the program waits for all the threads to be done calculating 
before continuing with the execution. 
 
The kernel function used for calculating the acoustic is given below under the header 
__global__ void ForwardPropagationKernel: 
 
__global__ void ForwardPropagationKernel(const unsigned int mr2, 
                                         const unsigned int mr1, 
                                         const cudaFloatingType wvnbr, 
                                         const cudaFloatingType wvnbi, 
                                         cudaFloatingType *r2pr, 
                                         cudaFloatingType *u2pr, 
                                         cudaFloatingType *u2pi, 
                                         const unsigned int mr1step, 
                                         const char LastPart, 
                                         cudaFloatingType *coolant_ellipse, 
                                         cudaFloatingType *distended_ellipse, 
                                         cudaFloatingType prostate_attenuation) 
 
const int si2 = blockDim.x * blockIdx.x + threadIdx.x ;//setting indexing for threads as a 1D grid 
if ( si2 >= mr2) // each data point is saved in mr2 and is indexed by si2 
    return; 
      temp_r = 0; 
      temp_i = 0; 
      for (int si1=0; si1<mr1step; si1++) // each source is saved in mr1 and is indexed by si1 
        {dx=PartSource[si1]-r2pr[si2]; 
          dy=PartSource[si1+mr1step]-r2pr[si2+mr2]; 
          dz=PartSource[si1+2*mr1step]-r2pr[si2+2*mr2]; 
          R=sqrt(dx*dx+dy*dy+dz*dz);// distance between source and data point 
          //get normal vector                                                                                                                                                                   
          dx=abs(dx/R); 
          dy=abs(dy/R); 
          dz=abs(dz/R); 
          //initialize intersection distance to zero, if we cross the ellipses then we will change them                                                                                         
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          R2=0; 
          R3=0; 
          R1=sqrt(intrp[0]*intrp[0]+intrp[1]*intrp[1]+intrp[2]*intrp[2]);// inside coolant ellipse 
          if (R1>=R){//inside coolant ellipse                                                                                                                                                   
            R1=R; 
          } 
          else { //point is between coolant ellipse and distended ellipse                                                                                                                       
            ellipse_intersection(CONST_distended_ellipse,dx,dy,dz,PartSource,si1,mr1step,intrp);//calculating 
ellipse intersection for both coolant ellipse and distended rectum ellipse 
            R2 = sqrt(intrp[0]*intrp[0]+intrp[1]*intrp[1]+intrp[2]*intrp[2]); 
            if (R2>=R){//inside distended ellipse                                                                                                                                               
              R2=R-R1; 
            } 
            else {//point is outside all ellipses                                                                                                                                               
              R2-=R1; 
              R3=R-R2-R1 
          atten_fact=-(CONST_coolant_ellipse[5]*R1 + CONST_distended_ellipse[5]*R2 +    
          CONST_prostate_attenuation*R3); 
          atten_fact=__expf(atten_fact);//*R);                                                                                             
          ti=atten_fact*Part_a1pr[si1]/R; 
          tr=ti; 
          __sincosf(R*wvnbr,&pSin,&pCos); 
          tr*=(Part_u1pr[si1]*pCos-Part_u1pi[si1]*pSin); 
          ti*=(Part_u1pi[si1]*pCos+Part_u1pr[si1]*pSin); 
          temp_r +=tr; 
          temp_i +=ti; 
        }//End of for si1                                                                                                                  
      u2pr[si2]+=temp_r; 
      u2pi[si2]+=temp_i; 
} 
 
BHTE Calculation algorithm  
 
 The thermal simulation was programmed as a Matlab function with a mexFunction used 
to execute the GPU code. The acoustic field required for treatment of the selected target site was 
determined using the technique previously explained. Using the masks created from the VHSMP, 
matrices were created to represent the tissue perfusion rate, thermal conductivity, specific heat, 
acoustic absorption and, for the coolant liquid, a flow rate matrix. These matrices were passed 
into global memory. Constant memory was used to store the exposure time, blood properties, 
initial temperature settings and the observation field creating an array of tissue information. The 
BHTE was then run in succession until a steady temperature state was reached (see section 3) 
with the Finite Difference Time Difference technique defined by Yin et al. (2006). The 
implementation of the Finite Difference Time Difference technique will now be explained. 
 The computation of the BHTE was modeled in Cartesian space and the discretized using 
equation A-2.  
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  (A-3) 
  
where:        
                   
        
Each element in the tissue array was assigned to a thread. As seen in equation A-3 each 
element in the array of data points is dependent on the elements in front and behind it. Therefore 
elements at the edge of each block will have a dependency on the block previous to it.  
To speed-up calculations, shared memory was used to store temporarily thermal 
properties of threads that were neighbors in the same thread block. As stated earlier each block 
of threads can only access the shared memory of that particular block and accessing global 
memory incorporates latency in memory access. Therefore to ensure that the boundaries of each 
block are properly calculated a padding technique in which an overlap of calculations was 
implemented. The thread indexing had to be changed from that seen in equation A-1 to the 
following: 
 
   (A-4)      
   (A-5) 
         (A-6) 
 
It can be seen in equations A-4 and A-5 that the indexing was reduced by doubling the padding 
to correct for both sides of the padding and then shifted for proper indexing on both sides of the 
tissue array. The indexing for the third dimension, equation A-6, is not indexed since the thread 
hierarchy is two dimensional. The third dimension was spliced and the index was iterated 
internally with a for loop.  
Now that the steady state conditions were determined the BHTE mexFunction was run 
again to determine the power ratio required for delivering the desired thermal dose. The acoustic 
absorption matrix was then multiplied by this ratio and the BHTE was run a final time to produce 
the desired thermal does and the lesion prediction was complete and displayed in a three 
dimensional image with examples seen in Figure 3-2. 
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